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REVIEW OF LITERATURE 
Introduction 
Bone is composed of dense connective tissue that forms the structural 
framework of vertebrates. There are approximately 206 bones in an adult human body 
and 270 in an infant. All these bones vary greatly in their shape and functions. The 
functions of bone can be organized into three categories: mechanical, synthetic and 
metabolic. Mechanical functions of bone include protection of internal organs, providing 
shape to the body and movement. For instance, brain is protected by skull and heart and 
lungs are enclosed in the ribcage. Bone, along with muscles, tendons, and ligaments 
function together to aid in movement of a part of or the whole body. A specialized 
mechanical function of bone is also involved in sound transduction, particularly in the 
middle ear. The synthetic function of bone tissue primarily comprises of haematopoesis. 
This takes place in the medullary cavity of long bones, where blood cells are produced 
from their progenitors. Bone also functions as a storage organ for minerals, growth 
factors and fat (energy reservoir) which formulates the bone tissue to play an essential 
role in body metabolism.  
Based on the structure, bone tissue can be categorized as compact bone or 
spongy bone. Compact bone, also called cortical bone, makes up the shaft of long 
bones and surfaces of other bones (Galante et al., 1970). Compact bone provides a 
smooth, white appearance to the bone and accounts for 80% of total bone mass of the 
skeleton. The fundamental functional unit of compact bone is known as Osteon or 
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Haversian system. Osteon is characterized as a long narrow cylinder that is 
approximately 10 mm in length and 0.2 µm in width (Buckwalter et al., 1995).  
Each osteon consists of a central canal or Haversian canal, which contains bone’s blood 
and nerve supplies. Surrounding the canal are concentric layers (lamellae) of compact 
bone tissue.  Lamellae consist of osteocytes lodged in spaces (lacunae) of mineralized 
bony matrix. These osteocytes within an osteon are connected to each other and to the 
central canal by fine cellular extensions called canaliculi.  These canaliculi facilitate the 
exchange of nutrients and metabolite waste between osteocytes and blood vessels. 
Osteons are connected to each other and periosteum by oblique channels called as 
Volkmann’s canals. 
Cellular and molecular structure 
 The major cells involved in bone growth and maintenance are osteoblasts, 
osteoclasts and osteocytes. Osteoblasts are responsible for production of major 
constituents of bone matrix, thereby commonly referred to as bone forming cells. They 
originate from multipotent mesenchymal stem cells that later differentiate to 
preosteoblasts and terminally differentiate into functional mature osteoblasts (Aubin et 
al., 1995). The transition from osteoprogenitors to mature osteoblasts is induced by 
several growth factors including insulin-like growth factor (IGF), platelet derived growth 
factor (PDGF), fibroblast growth factor (FGF) and transforming growth factor-β (TGF-β) 
(Aronow et al., 1990). A mature osteoblast synthesizes a collagen rich matrix (osteoid) 
which later mineralizes to form the mature bone. During mineralization, some of the 
osteoblasts get entrapped within the bony matrix and differentiate into osteocytes. On 
the contrary, some of the osteoblasts remain on the bone surface to form flat lining cells. 
Osteocytes are essentially osteoblasts that are trapped within the bony matrix. These 
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osteocytes undergo a change in morphology and develop numerous long cytoplasmic 
processes that occupy the canaliculi and facilitate the exchange of nutrients and waste. 
The functional activity of osteocytes is similar to the osteoblasts but has limited capacity 
of protein synthesis (Nefussi et al., 1991). 
 Another major cell involved during bone remodeling is the osteoclast which is 
responsible for bone resorption. Unlike osteoblasts, osteoclasts originate from 
hematopoetic monocyte-macrophage cell lineage (Gothlin and  Ericsson, 1976). 
Osteoclasts are found in contact with a bone surface and enclosed within a resorption 
lacuna (Howship’s lacuna). They are characterized by a giant size (up to 100 mm in 
diameter), multinucleated (usually 10 to 20 nuclei), ruffled border (foldings of the plasma 
membrane facing the bony matrix), sealing zone (the surrounding zone of attachment of 
osteoclast to the bony matrix) and a foamy appearance due to a greater concentration of 
vesicles and vacuoles (Gothlin and  Ericsson, 1976).   
Significance of bone related research 
  Over the past years, many research laboratories throughout the world including 
those at the academic and industrial levels have focused on a better understanding of 
the molecular mechanisms regulating bone formation and growth.  A major cause for this 
rise in research is explained by a steady increase in bone related diseases in humans. 
For instance, osteoporosis is one such disease which is on a steady rise in the U.S.A. 
and all over the world. Statistical estimates by the National Osteoporosis Foundation, 
U.S.A. revealed that about 44 million people are affected by osteoporosis in the U.S.A. 
and it is expected to increase to 52 and 62 million by 2010 and 2020, respectively 
(National Osteoporosis Foundation, 2010). In addition, osteoporosis related fractures 
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were estimated to cost 19 billion dollars in 2005 and are expected to rise to 25 billion 
dollars by 2025 (National Osteoporosis Foundation, 2010).  
 Primary osteoporosis is the most common metabolic disorder of the skeleton and 
has been extensively studied (Raisz and  Prestwood, 2000). This disease has been 
broadly classified into type1 (postmenopausal osteoporosis) and type 2 (senile 
osteoporosis) osteoporosis (Ralston, 1997). Osteoporosis is a disease characterized by 
reduced bone mineral density (BMD) and fragile bones leading to increased risk of 
fracture. The reduced BMD occurs due to an imbalance between bone formation and 
bone resorption. In a normal individual there exists a balance between bone formation 
and resorption to maintain bone mass. During osteoporosis, there is an increase in bone 
resorption without a compensatory increase in bone formation (Raisz and  Rodan, 
2003). The potential methods to improve the BMD in osteoporotic patients are either to 
increase the bone formation or to reduce the bone resorption (Ralston, 1997). To date, 
most research has focused on different methods to inhibit the bone resorption. Very 
recently, interest has been directed in understanding the process of bone formation 
during bone remodeling. A detailed investigation of the bone formation process would 
eventually help in developing potential methods to prevent or delay the onset of 
osteoporosis as well as other bone related diseases. 
 The process of bone formation depends on the number and activity of osteoblast 
cells. The number of osteoblasts present at the site of bone formation in turn depends on 
the lifespan and proliferation potential of osteoblasts (Manolagas, 2000). Bone formation 
is a complex process and is an integral part of bone remodeling. To identify and 
understand the regulation of the bone formation process, it is essential to know the 
different stages and complex processes involved during bone remodeling. 
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Bone remodeling 
Bone remodeling is a very complex process involving a series of highly regulated 
steps. The overall cascade of bone remodeling depends on the interactions of two cell 
lineages; osteoblastic and osteocalstic cell lineages (Eriksen, 1986). In a normal 
individual, there exists a balance between the amount of bone resorbed and the amount 
of bone formed. Bone remodeling occurs primarily on the inner or endosteal surfaces of 
bone and much less on the periosteal surfaces (Orwoll, 2003). Bone remodeling occurs 
in small packets of cells known as basic multicellular unit (BMUs) at focally discrete 
points on the inner surfaces of bone. Each BMU is geographically and chronologically 
separated from other packets of cells.  At a particular point of time, remodeling at each 
BMU will be asynchronous; one site may be at the phase of resorption while the other at 
reversal or formation phases (Parfitt, 2002). This suggests that cellular and molecular 
events in bone remodeling are controlled by either autocrine or paracrine factors. 
Stages of bone remodeling include 1) resorptive phase, 2) reversal phase, 3) 
formative phase and 4) resting phase.   
Resorptive phase 
The bone resorption cascade includes a series of steps targeting the removal of 
bone by oseoclasts. Osteoclasts, also known as bone eating cells, have a 
haematopoetic origin and are derived from the monocyte macrophage cell lineage 
(Roodman, 1996). The structure and function of osteoclasts in bone resorption have 
been well characterized (Roodman, 1996). The first step involves the recruitment of 
osteoclast progenitors from haematopoetic tissues, such as bone marrow, to the site of 
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bone resorption. They then proliferate and differentiate to form mature osteoclasts 
through a cell-cell interaction with osteoblast stromal cells. Differentiation into mature 
osteoclasts is regulated by receptor activator for nuclear factor κ B receptor ligand 
(RANK-RANKL) binding. RANKL produced by cells of osteoblast lineage binds to its 
receptor present on the haematopoetic progenitors to initate osteoclast differentiation 
(Martin and  Sims, 2005). Once a mature osteoclast is formed, it is followed by removal 
of osteoid layer on the surface of bone by lining osteoblasts. These osteoblasts secrete 
several proteolytic enzymes including matrix metalloproteinases (MMPs), collagenase 
and gelatinase (Meikle et al., 1992). This allows easy access for osteoclasts to the 
underlying mineralized matrix. Osteoclasts adhere to the bone surface through a 
receptor–ligand recognition mechanism. Amongst the integrin family of adhesion 
receptors, a specific type of vitronectin receptor (Lakkakorpi et al., 1991) binds to 
extracellular matrix (ECM) proteins inducing the polarization of osteoclasts. These 
processes lead to a ruffled border and clear or sealing zone formation in osteoclasts. 
The clear zone is an organelle free region of cytoplasm with thick bands of actin rings 
that  serves for tight attachment of osteoclasts, formation of a resorption lacuna 
commonly known as ‘Howship’s lacuna’ and thus restricting the resorptive surfaces on 
the bone (Vaananen and  Horton, 1995). The next step comprises the activation of 
adhered osteoclasts and resorbing the bone surfaces within the lacunae.  This is 
mediated by the H+ - ATPase pump present in the ruffeld border of osteoclasts (Blair et 
al., 1989; Nakamura et al., 1994). The pump transports protons into the Howship’s 
lacunae, providing an acidic environment for the dissolution of bone minerals.  
Proteolytic enzymes, primarily cathepsin K (Drake et al., 1996) and MMPs including 
gelatinase B and collagenase (Hill et al., 1994), and lysosomal enzymes are also 
released from the ruffled border to degrade and dissolve the organic matrix in bone. The 
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degraded products are endocytosed through the center of the ruffled border, packaged 
as transcytotic vesicles, transported to the functional secretory domain of the osteoclasts 
facing the bone marrow and exocytosed (Nesbitt and  Horton, 1997). Osteoclasts have a 
limited life span of 12 to 13 days and therefore, recruitment of osteoclast precursors into 
the site of bone resorption has to continually take place until desired bone resorption has 
occurred. 
Reversal phase 
After a desired amount of bone resorption has occurred, it is followed by a phase 
of reversal which lasts for approximately 9 days (Hill et al., 1997). During this phase the 
osteoclastic activity is arrested and thus bone resorption is put to an end. To date, the 
regulatory mechanisms that occur during this phase have not been well understood. 
Many researchers have suggested possibilities leading to the end of bone resorption. 
Firstly, apoptosis or programmed cell death of osteoclasts can be a major cause for the 
arrest of osteoclastic activity (Wakeyama et al., 2007).  Zaidi (1990) provided alternate 
hypotheses that there is a large increase in the concentration of calcium within 
Howship’s lacunae during bone resorption. The rise in calcium concentration causes 
rapid cell retraction, inhibiton of proteolytic and lysosomal enzyme release into the 
lacunae, and finally inhibit bone resorption (Zaidi, 1990). A third suggestion put forward  
is the release of TGF-β or other peptides from the bony matrix during bone resorption 
which will inactivate osteoclasts and chemotactically attract osteoblasts to the site of 
bone resorption (Pfeilschifter and Mundy, 1990). Thus, the inactivation of osteoclasts 
marks the end of reversal phase and the beginning of phase of bone formation.  
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Formative phase 
The process of bone formation includes a series of events beginning from 
chemotactic attraction of osteoblast precursors to the site of bone formation, proliferation 
and differentiation of osteoblast progenitors into mature osteoblasts, formation of organic 
matrix and finally mineralization of bone.  The chemotactic attraction of osteoblasts or 
their precursors onto the site of bone resorption marks the beginning of the process of 
bone formation. As discussed above, chemotaxis of osteoblast progenitors is mediated 
by local factors produced during the resorption process. One such factor, TGF-β is 
chemotactic for bone cells and has been shown to be released by resorbing bone 
cultures (Pfeilschifter and  Mundy, 1987). Similarly, structural proteins like collagen have 
also been demonstrtated to be chemotactic for osteoblast and/or osteoblast progenitors 
(Mundy et al., 1982).  
The second major step in the formative phase is the proliferation and 
differentiation of osteoblast precursors into mature osteoblasts. The process of bone 
formation involves a cascade of events starting from recruitment of mesenchymal cells 
to osteoblastic lineage, differentiation into pre-osteoblasts and then to osteoblasts and 
maturation of functional osteoblasts that secrete bony matrix (Aubin et al., 1995). 
Specifically, the mesenchymal stem cells are pluripotent in nature and can give rise to 
many cell lineages including the osteogenic line. These mesenchymal stem cells have 
unlimited self renewal capacity implying an extensive proliferative potential. Once these 
stem cells are recruited to osteogenic line, they are referrred to as 
osteochondroprogenitor cells (Aubin et al., 1995). They are very similar to mesechymal 
stem cells but with limited self renewal capacity. The osteochondroprogenitors cells can 
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either be directed to the osteogenic lineage forming preosteoblasts or directed to the 
chondrocyte lineage forming prechondroblasts. Although the preosteoblasts are similar 
to osteoblasts histologically and ultrastructurally, they do not acquire many of the 
differentiated characteristics of a fully mature osteoblast. The preosteoblasts have 
limited proliferative capacity and begin to differentiate to functional osteoblasts. A fully 
mature osteoblast is characterized by the ability to synthesize alkaline phosphatase 
(ALP), bone marix proteins including collagen type-I (Coll-I), and several non 
collagenous proteins including osteocalcin (OCN), bone sialoprotein (BSP), and 
osteopontin (Aubin et al., 1995). Since the identification of these characteristic proteins, 
they have been used as markers of osteoblast differentiation. Several studies in mice 
and rats demonstrate that these differentiation markers are not readily expressed in 
preosteoblasts (Helder et al., 1993). For instance, BSP is not readily detectable in 
preosteoblasts but is highly expressed in osteoblasts (Bianco et al., 1993). Furthermore, 
markers like Coll-I and OCN are weakly expressed in rat preosteoblasts but highly 
expressed in the mature osteoblasts (Mark et al., 1988; Helder et al., 1993). These 
functional osteoblasts are the bone froming cells, which form the mineralized bone. 
The osteoblastic lineage is also regulated by local growth factors such as TGF- β 
(Centrella et al., 1991), IGF-I and IGF-II (Schmid et al., 1992), acidic and basic FGF, 
bone morphogenetic proteins (BMPs) -2, -3, -4, -6, -7 and PDGF (Rydziel et al., 1992), 
as well as homones including parathyroid hormone (PTH), growth hormone (GH) and 
sex hormones, transcription factors including runt-related transcription factor 2 (Runx2), 
osterix (Osx), activating transcription factor 4 (ATF4), activator protein 1 (AP1) and many 
others (Nakashima et al., 2002; Xiao et al., 2005; Karsenty, 2008). These transcription 
factors and their regulation in bone formation are discussed in detail in the following 
sections.  
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Finally, mature osteoblasts begin to lay down osteoid from the bottom of the 
resorption cavity and continue to form until the cavity is filled. Meanwhile the osteoid 
begins to mineralize at a rate of 1µm/day (Aubin et al., 1995). The osteoblasts at the 
bottom of the cavity are robust in shape and vigorous, forming a thick layer of osteoid. 
Termination of the osteoblastic activity occurs through a negative feedback inhibition. 
This has been demonstrated by the actions of osteoclast inhibitory lectin (OCIL) protein 
that inhibits both osteoblast and osteoclast differentiation (Nakamura et al., 2007). 
Alternatively, cessation of osteoblastic activity is regulated by the apoptosis of 
osteoblasts. Hill et al., (1997) reported that tumor necrosis factors released from the 
neighboring bone marrow cells could induce apoptosis in osteoblasts (Hill et al., 1997). 
Sclerostin, a protein secreted from the osteocytes, has also been shown to inhibit bone 
formation (Sutherland et al., 2004). In vitro studies have demonstrated that sclerostin 
inhibits proliferation, impairs mineralization and stimulates apoptosis of osteoblasts by 
interfering the Wnt and BMP signaling pathways (Sutherland et al., 2004). 
Resting phase 
The mineralization of newly formed bone marks the beginning of resting phase 
(Hill et al., 1997). During mineralization, some of the osteoblasts get trapped in the 
mineralized bony matrix to form osteocytes. These osteocytes later develop processes 
and form connections with adjacent osteocytes. Osteoblasts on the outer surface 
differentiate to form lining cells. A complete bone surface is restablished and maintained 
until the next wave of remodeling begins. 
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Regulation of bone remodeling 
The process of bone remodeling is tightly regulated by several factors including 
hormones, growth factors and transcription factors at both systemic and local levels. 
They exert their effect on recruitment, proliferation and differentiation of both osteoblastic 
and osteoclastic lineage cells. These factors aid in the maintenance of normal bone 
mass (Canalis, 1983).  The major hormones that regulate bone remodeling include 
polypeptide hormones (PTH, calcitonin, and GH), steroid hormones [1, 25-
dihydroxyvitamin D3 (Vit D3), glucocorticoids and, sex steroids] and thyroid hormones 
(TH). This review will briefly discuss the role of the major hormones in regulating bone 
homoeostasis and development. 
Parathyroid hormone (PTH)  
PTH functions as the mediator of bone remodeling and important regulator of 
calcium homeostasis. It increases the serum calcium concentrations by direct actions on 
bone and kidney (Swarthout et al., 2002). PTH acts on the kidney to increase the renal 
tubular calcium reabsorption. Action of PTH on the intestine stimulates the synthesis of 
Vit D3 increasing the intestinal absorption of calcium (Potts et al., 1997). Besides the 
role of PTH on calcium homeostasis, recent studies demonstrate the effect of PTH on 
osteoclast and osteoblast activity. PTH, along with PTH-related peptide (PTHrP) 
interacts with receptors on osteoblasts to produce osteoclastogenic factor RANKL which 
initiates osteoclast differentiation. Thus, PTH indirectly activates osteoclasts resulting in 
increased bone resorption (Teitelbaum, 2000). On the other hand, PTH has been 
demonstrated to be an anabolic factor in vitro and in vivo. It is known to stimulate the 
expression of IGF-I, IGF-II, and IGF binding proteins (IGFBPs) thereby demonstrating 
anabolic effects of PTH on bone formation (Canalis et al., 1988). Since the intermittent 
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administration of PTH stimulates the bone formation, PTH has potential medical 
application for the treatment of osteoporosis (Lindsay et al., 1997; Cosman and  Lindsay, 
1998).  
Sex steroids 
Estrogen and testosterone play an important role in bone and mineral 
metabolism. For instance, reduced estrogen concentrations lead to a marked reduction 
in BMD, thus describing the major rationale for post-menopausal osteoporosis (Syed 
and  Khosla, 2005).  Normal concentrations of estrogen in the body reduce the 
osteoclast formation by decreasing the receptiveness of osteoclast progenitor cells to 
RANKL (Srivastava et al., 2001). Estrogen has also been shown to protect bone mass 
through induction of osteoclast apoptosis (Kameda et al., 1997). Similar to estrogens, 
androgens also play an essential function in bone growth. They exert their action 
through androgen receptors present on all types of bone cells (Sato et al., 2002). Normal 
amount of androgen receptors are required for the suppressive effects of androgens on 
osteoclastogenesis (Kawano et al., 2003). This explains the reduced risk of 
osteoporosis, greater mineral density and stronger bones in males. 
Growth Hormone (GH) and insulin-like growth factors (IGF) 
GH is a polypeptide hormone produced from the anterior pituitary gland.The 
synthesis and release of GH is regulated by growth hormone releasing hormone 
(GHRH) and somatostatin (Giustina and  Veldhuis, 1998). GHRH promotes while 
somatostatin inhibit the release of GH from the anterior pituitary gland. One of the most 
important functions of GH is that it is essential for normal bone development. It has both 
direct effect and indirect effects on bone. The direct effect of GH on bone is explained by 
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the presence of GH receptors on osteoblasts and chondrocytes (Barnard et al., 1988). 
Furthermore, in vitro studies have demonstrated that GH stimulates the proliferation rate 
of cells of osteoblastic lineage (Kassem et al., 1993) and expression of BMPs that are 
important for osteoblast differentiation (Li et al., 1998; Canalis et al., 2003), thus 
emphasizing the direct effect of GH on osteoblasts. The indirect effects of GH are 
mediated by IGF. GH stimulates the release of IGF-I from the liver, which then circulates 
through blood and exerts its endocrine actions on target tissues such as bone. 
Additionally, IGF-I is also produced locally from bone and exerts autocrine or paracrine 
effect on bone (Le Roith et al., 2001). IGF-I and IGF-II are the most abundant growth 
factors present in the skeletal tissue and the bioavailability of these factors are regulated 
by IGFBPs. These IGFBPs are often found bound to the circulating IGF-I or complexed 
with IGF-I produced locally in tissues. To date, six IGFBPs have been identified. Of 
these, IGFBP-3 and -5 stimulate whereas IGFBP-2, -4 and -6 primarily inhibit the actions 
of IGF-I on bone (Jones and  Clemmons, 1995). In vivo studies in mice further confirm 
the direct and indirect roles of GH and IGF on longitudinal bone growth.  Specifically, 
mutated mice lacking GH and IGF-I had a severe reduction in tibial length and width 
than either mutant alone (Giustina et al., 2008) . These skeletal effects occur as a result 
of complex interactions between GH, circulating and locally produced IGF and IGFBPs 
(Giustina et al., 2008). 
Growth factors 
Besides IGF-I and -II, there are many other growth factors including FGF, PDGF, 
BMPs and Wnt family of proteins that regulate bone formation and remodeling. 
Functionally, FGF and PDGF are osteoblast mitogens. One among several types of FGF 
is FGF-2. In vitro studies report that it stimulates DNA synthesis and proliferation of 
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osteoblast precursors that later mature to form functional osteoblasts (Canalis et al., 
1988). However, FGF-2 does not have any action on the differentiation and function of 
osteoblasts. Infact, it inhibits the expression of markers of osteoblast function such as 
ALP (marker of early osteoblast diferentiation), OCN (marker of late osteoblast 
differentiation) and osteopontin (Canalis et al., 1988). This inhibitory effect of FGF-2 on 
differentiation of osteoblasts is mediated by induction of transcription factor Sox2 and 
inhibition of Wnt signaling. Similar to FGF-2, PDGF also increases the number of 
osteoblasts and does not stimulate the differentiation and function of osteoblasts 
(Canalis et al., 1992).   
BMP, a member of the TGF-β super family, is comprised of proteins that are 
expressed primarily in bone and other extraskeletal tissues (Daluiski et al., 2001). Of the 
many different forms, BMP-2,-4 and -6 are the primary BMPs expressed in bone and 
regulate osteoblast cell differentiation and function via Smad (Sma and Mad related 
family of proteins) or MAP (mitogen activated protein) kinase signaling pathways 
(Miyazono, 1999). BMPs induce endochondral ossification and chondrogenesis. They 
stimulate the maturation and function of chondrocytes with an increase in expression of 
type II and type X collagens (Canalis et al., 2003). Several BMP antagonists have 
recently been identified that inhibit BMP mediated signaling pathways by binding BMPs,  
including noggin, follistatin, chordin and dan family of proteins (Zimmerman et al., 1996; 
Gazzerro et al., 2007). Activin, a BMP related protein stimulates osteoblast proliferation, 
collagen synthesis, endochondral formation and enhances fracture healing (Centrella et 
al., 1991).  
Another growth factor that regulates osteoblast differentiation and bone formation 
is the Wnt (wingless-int) family of proteins. In skeletal tissue, Wnt uses canonical Wnt/β-
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catenin signaling pathway (Westendorf et al., 2004). Wnt receptor mutations lead to 
severe impairment of bone mass suggesting a critical role in skeletal tissue (Westendorf 
et al., 2004). Interference of this pathway at different stages leads to many clinical 
manifestations.  Wnt or β-catenin deletion results in decreased osteoblastogenesis and 
increased osteoclastogenesis, whereas overe expressing the same leads to enhanced 
osteogenesis and impaired bone resorption (Glass et al., 2005; Holmen et al., 2005), 
suggesting the importance of Wnt in normal bone growth. 
Transcriptional control of osteoblast function 
Aside from hormones and growth factors, the process of bone formation is tightly 
regulated by different transcription factors. Several transcription factors have been 
identified that play important roles during skeletal development (Komori et al., 1997; 
Karsenty, 2008; Karsenty et al., 2009).  Recent advances in mouse and human genetics 
have led to identification of these factors. Based on different stages of bone 
development, these transcription factors primarily function either in chondrocyte or 
osteoblast differentiation.  Within a lineage (osteoblastic or chondrocytic), these 
transcription factors regulate different stages of differentiation. For a better 
understanding, transcriptional regulation during skeletal development has broadly been 
categorized by researchers into two categories: 1) transcription factors that regulate 
chondrogenesis and 2) transcription factors that regulate osteoblastogenesis.  This 
review will primarily focus on transcriptional regulation of osteoblasts. 
As previously discussed, the process of bone formation involves a cascade of 
events starting from recruitment of mesenchymal cells to osteoblastic lineage, 
differentiation into pre-osteoblasts and then to osteoblasts and maturation of functional 
osteoblasts that secrete bony matrix.  These different steps are governed by different 
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transcription factors. Some of the most important transcription factors are discussed 
below.  
Figure 1  
Transcriptional control of osteoblast and chondrocyte differentiation 
 
          
                                                                               
Runt-related transcription factor 2 (Runx2) 
 Runx2, a member of the runt family of transcription factors is known as the 
master gene of bone formation (Karsenty, 2008). All members of this family contain a 
highly conserved domain called the runt domain. It is through this domain whereby 
Runx2 interacts with nuclear proteins. Runx2 is the earliest and most important 
determinant of osteoblast differentiation (Ducy et al., 1997; Komori et al., 1997). 
Molecular and genetic studies revealed that it is involved in the recruitment of 
mesenchymal cells into osteoblastic lineage. Runx2 also regulates the differentiation of 
                                  Adapted from Karsenty, 2008 
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mesenchymal cells to osteoprogenitor cells and then to mature osteoblasts. The 
expression of Runx2 occurs at very early stages of mesenchymal cell lineage and is 
observed in the developing embryo by E9.5 prior to bone formation (Lengner et al., 
2002; Romero-Prado et al., 2006). The forced expression of Runx2 causes 
mesenchymal cells of other lineages to express osteoblast specific genes that are 
directly regulated by Runx2 (Ducy et al., 1997). Similar to the findings observed in vitro, 
studies in mice lacking Runx2 resulted in skeleton completely deprived of osteoblasts 
(Komori et al., 1997). These studies demonstrate that Runx2 is one of the most 
important transcription factors for osteoblast differentation. Recent studies have shown 
that an optimal expression of Runx2 is favorable to bone growth (Liu et al., 2001). 
Transgenic mice over expressing Runx2 in osteoblasts developed osteopenia with 
multiple fractures. These bones showed impaired bone mineralization with significant 
reduction in mature osteoblasts (Liu et al., 2001). This suggests that Runx2 negatively 
controls osteoblast terminal differentiation. The significance of Runx2 in 
osteoblastogenesis indicates a tight regulation of its activity and expression by many 
other transcription factors or protein-protein interactions or protein-DNA interactions 
(Karsenty, 2008).  
Osterix (Osx) 
 Osx, a zinc finger-containing transcription factor, is specifically expressed by 
osteoblasts and required for osteoblast differentiation. The first evidence of Osx’s role in 
osteoblasts was revealed by Nakashima and coworkers in 2002 (Nakashima et al., 
2002). They observed that Osx deficient mice resulted in perinatal lethality and impaired 
matrix mineralization only in bones that underwent intramembraneous ossification 
(Nakashima et al., 2002). The endochondral ossified bone showed some matrix 
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mineralization stating that Osx, unlike Runx2, is not required for chondrocyte 
hypertrophy. They also observed that Osx is not expressed in Runx2 deficient mice 
whereas Runx2 is expressed in Osx deficient mice, suggesting that Osx is a 
downstream target for Runx2 (Nakashima et al., 2002). Osx transcription is positively 
regulated by Runx2 and it acts by directing pre-osteoblasts to immature osteoblasts 
(Celil et al., 2005). Unlike Runx2, the mechanism of action and the molecular pathways 
that regulate Osx expression is poorly understood.  
Activating transcription factor 4 (ATF4) 
  ATF4 is an osteoblast enriched transcription factor belonging to cAMP reponse 
elements binding (CREB) family of proteins (Xiao et al., 2005). The gene that encodes 
for ATF4 is expressed in many cell types but accumulation of protein takes place in 
osteoblasts cells.  ATF4 is required primarily for late osteoblast differentiation.  The 
major action of ATF4 on osteoblast differentiation takes place by its interaction with 
Runx2 to regulate the transcriptional activity of OCN, a late osteoblast differentiation 
marker (Xiao et al., 2005). ATF4 also controls amino acid import into the osteoblasts. 
This function of ATF4 is significant for cells like osteoblasts that secrete large amounts 
of protein (Harding et al., 2003).  Besides these functions in osteoblasts, ATF4 also 
favors osteoclast differentiation and bone resorption (Elefteriou et al., 2005).  
Activator protein1 (AP1) 
 AP1 is a family of transcription factors comprised predominantly of proteins in the 
Fos and Jun families (Wagner, 2002). Generating mouse models with loss- or gain-of-
function of these families of proteins demonstrated AP1 proteins to be important 
regulators of bone formation (Wagner, 2002). Of these many proteins, c-Fos was the 
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first transcription factor identified to control osteoblast proliferation and gene expression. 
Specifically, overexpression of c-Fos in mice resulted in osteosarcoma and deletion of c-
Fos in mice led to osteopetrosis signifying the importance of AP1 family of transcription 
factors (Grigoriadis et al., 1993). Similarly, other members of this family like Fra-1 and 
JunB also promote bone formation and bone mass with increased number of osteoblasts 
(Eferl et al., 2004; Kenner et al., 2004) . 
Other transcription factors involved in osteoblast function 
 There are many other transcription factors that regulate osteoblast proliferation, 
differentiation and apoptosis. They either act directly on osteoblasts or indirectly by 
interacting with the above described classical transcription factors to control bone 
formation and bone growth. Some of the key transcription factors involved inbone 
formation and osteoblast function are discussed in more detail below. 
Genetic and molecular studies demonstrated that several transcription factors 
belonging to the family of homeobox proteins [Msx1, Msx2, distal-less homeobox (Dlx)3, 
Dlx5 and Dlx6] may play a role in osteoblast differentiation (Shirakabe et al., 2001; 
Hassan et al., 2004). These proteins act either as a transcriptional activator or repressor 
to regulate bone growth. Mice deficient in Msx2 demonstrated delayed skull ossification 
and reduced expression of Runx2 (Shirakabe et al., 2001). Consistent with the above 
findings, in vitro studies demonstrate that Msx2 regulates osteoblast proliferation and 
apoptosis (Lynch et al., 1998). Similarly, Dlx 3 and Dlx5 are expressed at all stages of 
osteoblast differentiation, with an increase in expression as osteoblasts mature. They 
also function indirectly by enhancing the expression of Runx2 and OCN (Holleville et al., 
2007).  Another group of transcription factors are helix-loop-helix proteins that regulate 
osteoblast maturation. Of these, Twists (Twist-1 and Twist-2) are the major proteins that 
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negatively regulate early osteoblast differentiation (Guenou et al., 2005). Twist-2 
interacts with Runx2 to reduce the expression of Runx2 in osteoblasts, thereby 
regulating osteoblast proliferation and differentiation (Guenou et al., 2005). Besides 
Runx2, there are other transcription factors that play a role in lineage determination. One 
among them is proliferation–activated receptor γ2 (PPAR γ2), which is involved in the 
differentiation of mesenchymal cells into osteoblasts. In addition, PPAR γ2 binds to 
Runx2 and inhibits its transcriptional activity (Akune et al., 2004). This function of PPAR 
γ2 has been validated by both in vitro and in vivo studies in transgenic mice (Akune et 
al., 2004).  
 In addition to all these transcription factors, recent advances in mouse and 
human genetic studies have led to the identification of novel transcription factors in 
osteoblasts (Gutierrez et al., 2002; Jeon et al., 2003; Govoni et al., 2009). To date, very 
little information is known about the action of these factors on osteoblast function 
including proliferation, differentiation and apoptosis. As described earlier, the bone 
formation cascade involves a complex series of events that are tightly regulated by 
growth factors, hormones, and, transcription factors during different stages of osteoblast 
lineage. A novelfamily of transcription factors involved in early limb development and 
osteoblast function is described in more detail. 
T-box (Tbx) family  
  One among the novel transcription factors that plays an important role in 
development of various animal species is Tbx family. The Tbx family of transcriptional 
factors is very primordial and highly conserved among most species of animals 
(Papaioannou and  Silver, 1998). Tbx family has gained a recent significance in 
molecular research due to its association with many human diseases including genetic 
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disorders and various types of cancers. Since then, there has been much interest in 
understanding the molecular roles of Tbx genes during development. 
Evolutionary history and significance of Tbx family  
  Tbx family was first described in 1927 with the discovery of Brachury (T locus) 
that plays an important role in early vertebrate development (Dobrovolskaia-Zavadskaia, 
1927). Mutational studies in mice led to the identification of this gene. Mice, 
heterozygous for Brachyury mutation had a truncated tail and homozygote mutants 
showed embryonic lethality due to improper notochord and allantois formation 
(Dobrovolskaia-Zavadskaia, 1927). The short tail in heterozygotes was the hallmark of 
this study and consequently led to the designation of T (tail) for the Tbx family. Following 
this discovery of Brachyury, the embryological defects caused by T mutation were 
studied until the gene was cloned (Herrmann et al., 1990) and found to be a transcription 
factor (Kispert et al., 1995). This research was a significant breakthrough and since then, 
many laboratories have reported Tbx genes in species varying from C.elegans, 
Drosophila, sea urchins, chick, zebrafish, mouse and humans (Papaioannou, 2001). To 
date, over 18 T-box transcription factors have been identified in the human genome and 
have been grouped into five subfamilies: Brachyury, T-brain1, Tbx1, Tbx2 and Tbx6 
subfamilies (Papaioannou, 2001; Wilson and  Conlon, 2002). 
 Another attribute of Tbx family to gain much recent medical importance is the 
linkage of Tbx genes to several human disorders. They include Holt-Oram syndrome 
(Tbx5), Ulnar-mammary syndrome (UMS; Tbx3), DiGeorge syndrome (DGS; Tbx1), 
ACTH deficiency (Tbx19) and cleft palate with ankyloglossia (Tbx22). UMS is caused by 
haploinsufficiency of Tbx3 gene (Bamshad et al., 1997). This syndrome is characterized 
by posterior limb deficiency or duplication, hypoplasia and dysfunction of mammary 
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gland, genitals, teeth and hair (Bamshad et al., 1997; Bamshad et al., 1999). Mutations 
in Tbx5 have been identified as the cause of Holt-Oram Syndrome (Basson et al., 1997). 
This syndrome is characterized by cardiac and skeletal congenital abnormalities 
(Basson et al., 1997). Abnormalities in the heart include ventricular and atrial septal 
defects and impaired conduction system. Skeletal defects primarily affect upper 
forelimbs (Basson et al., 1997; Li et al., 1997). Another member of this family, Tbx19 
(Tpit) was recently identified to activate expression of pro-opiomelanocortin (POMC) 
leading to reduced ACTH production and ultimately adrenal insufficiency. The DGS is 
associated with deletion of a small segment, designated as q11, in chromosome 22. The 
features of this syndrome vary widely from congenital heart defects, palate defects, 
hypoplastic thymus and parathyroids, facial dysmorphism and learning disabilities (Ryan 
et al., 1997). Very recent studies show that Tbx1-/- mice can recreate many aspects of 
Digeorge syndrome phenotype in mice (Jerome and  Papaioannou, 2001; Lindsay et al., 
2001). Further studies are needed to confirm the specific role of Tbx1 in DGS.  
 The five Tbx genes discussed above play significant roles in inherited human 
disorders. In addition, recent evidence suggests a possible role of Tbx genes, including 
Tbx2 and Tbx3, in cell cycle regulation in various tissues and thus contributing to the 
recent medical importance of Tbx family.  
T-box structure (general) 
 All members of this family are transcription factors (DNA binding proteins) that 
are either activators or repressors of transcription. Tbx proteins generally range in size 
from 50 to 78 kDa. From many reports on the structure of Tbx proteins, it can be 
concluded that Tbx proteins are comprised of two functional and structural domains, a 
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sequence specific DNA–binding domain and a transcriptional regulatory domain (Smith, 
1999; Papaioannou, 2001).  
The sequence specific DNA binding domain is referred to as T-box (Kispert and  
Hermann, 1993; Conlon et al., 2001). The T-box is a comparatively large domain making 
up to one third of the protein. There are varying degrees of homology across this T-box 
domain within a Tbx subfamily. However, there are specific residues within the T-box 
that are 100% conserved (Wilson and  Conlon, 2002). This observation ultimately 
promoted the classification of Tbx family into 6 subfamilies. The positions of these 
domains vary between different members of this family but are regularly placed closer to 
amino terminus of the protein. The second domain present in these proteins is a 
transcriptional regulatory domain that functions either as a transcriptional activator or 
repressor. In most of the Tbx protein studies, these domains are located at the carboxy-
terminal portion of the protein. 
T-box functions 
 The different members of Tbx family are expressed during different stages of 
development and in several tissues including the skeleton, kidney, lungs, liver, 
mammary gland, muscle and nervous system (Papaioannou and  Silver, 1998).The 
functions of Tbx genes have been best studied through  genetics and phenotypes of 
mice and human mutated for different Tbx genes. Amongst the various tissues studied 
for the role of Tbx transcription factors, cardiac and skeletal systems attain the prime 
importance. 
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Role of Tbx genes in cardiac system 
Identification of Tbx5 gene, the responsible candidate for congenital heart 
defects (Basson et al., 1999), introduced a lot of interest in determining the role of other 
Tbx genes in cardiac development. The Tbx genes that play an essential role in cardiac 
development primarily include Tbx1, Tbx2, Tbx3, Tbx5, Tbx18 and Tbx20 (Plageman 
and  Yutzey, 2005). All these factors put together regulate cardiac lineage recruitment, 
chamber specification, valve formation, epicardial development and specialization of the 
conduction system. A few of these Tbx factors regulate cardiac gene expression. 
Specifically, atrial natriuretic factor (ANF; required for water and Na+/K+ homeostasis) 
and connexin 40 (Cx40; a gap junction protein), have been identified as Tbx target 
genes. To date, they are the most extensively studied Tbx target genes in the heart. In 
vitro studies have shown that Tbx5 acts as an activator of ANF and Cx40 while Tbx2 and 
Tbx3 represses their expression (Habets et al., 2002; Christoffels et al., 2004; Hoogaars 
et al., 2004). These studies suggest the fact that Tbx genes play an essential role in the 
embryonic development of heart. 
Role of Tbx genes in skeletal system 
Another major system tightly regulated by Tbx genes is the skeletal system. 
Since the identification of Tbx genes, Tbx3 and Tbx5, as the responsible candidates for 
ulnar-mammary syndrome and Holt-oram syndrome, respectively in 1997, research has 
focused on the role of Tbx genes on limb bud development (Bamshad et al., 1997). 
Another Tbx gene, Tbx4 has recently been attributed for small patella syndrome. This is 
caused by hemizygous mutations in Tbx4 leading to aplasia or hypoplasia of patella and 
anomalies of pelvis and feet (Bongers et al., 2004). To date, seven Tbx genes, namely 
T, Tbx2, Tbx3, Tbx4, Tbx5, Tbx15 and Tbx18, have been identified that are highly 
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expressed in the limb buds. Of these, Tbx4, Tbx5 Tbx2 and Tbx3 have been most 
extensively studied to understand their specific regulation during embryonic and 
postnatal skeletal development. 
Tbx4 and Tbx5 are two closely related Tbx genes that are essential for normal 
limb bud development (Chapman et al., 1996a; Gibson-Brown et al., 1996a). The major 
functions of these Tbx genes include initiation of limb bud outgrowth and specification of 
forelimb and hindlimb identities. Most of the genes that are involved in limb development 
are expressed similarly in forelimb and hindlimb, but Tbx5 is only expressed in the 
forelimb and Tbx4 is only expressed in the hindlimb (Chapman et al., 1996a; Gibson-
Brown et al., 1996a). Due to the differential expression of Tbx4 and Tbx5 during limb 
bud growth, they are supposedly involved in specifying the structural differences 
between forelimb and hindlimb. 
Tbx15 and Tbx18 are two closely related Tbx genes with 93% sequence 
homology (Singh et al., 2005). Tbx15 is expressed in the murine mesenchyme, 
pharyngeal apparatus and the craniofacial region (Candille et al., 2004).  Genetic models 
of transgenic mice were created to determine the function of Tbx15 on skeletal 
development. Homozygous null mutation of Tbx15 led to many skeletal defects in mouse 
embryos (Singh et al., 2005). These embryos showed a reduced bone size and altered 
bone shape including limbs. On the other hand, mice carrying only one functional copy 
of Tbx15 were normal and survived to adulthood (Singh et al., 2005). Similar to Tbx15, 
Tbx18 is also greatly expressed during early embryonic development in mouse. It is 
expressed in the somites, resulting sclerotome (vertebrae) and also in the limb bud 
mesenchyme. Inactivation of one allele of Tbx18 did not result in any malformations, 
while inactivation of both alleles of Tbx18 resulted in early postnatal death and were 
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characterized by severe skeletal malformations of vertebrae and ribs (Bussen et al., 
2004; Singh et al., 2005). 
Tbx3 is another member of T-box family playing essential role during bone 
development both embryonically and postnatally. As explained earlier, UMS 
demonstrated the significance of Tbx3 during embryonic limb bud development 
(Bamshad et al., 1997). Further studies on Tbx3 have shown that it may play an 
important role during postnatal bone development (Govoni et al., 2006). It has been 
demonstrated that Tbx3 is expressed in adult mouse bone and is regulated by many 
growth factors (GH, BMP-7 and Wnt3a) and regulates osteoblast function (Govoni et al., 
2006; 2009). Specifically, knocking down the expression of Tbx3 using siRNA inhibited 
osteoblast proliferation (Govoni et al., 2006). Further studies showed that over 
expression of Tbx3 suppresses the differentiation of osteoblasts and is involved in 
regulating the expression of key transcription factors involved in osteoblast differentiation 
(Govoni et al., 2009). 
Tbx2 
Structure 
Tbx2 belongs to the Tbx2 subfamily of Tbx transcription factors that includes 
Tbx3, Tbx4 and Tbx5. Tbx2 is located on chromosome 11 in humans and has been 
mapped to chromosome17q23 in mice (Bollag et al., 1994; Campbell et al., 1995). Tbx2 
is comprised of 3,562 bp and 3,378 bp in mouse and human respectively with seven 
exons. Similar to other Tbx genes, Tbx2 has a T-box DNA binding domain and a 
transcriptional repressor domain. The human T-box domain shows 90%DNA and 96% 
peptide sequence homology to the mouse (Law et al., 1995). The T-box domain is 
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located at amino acid postion 106-289 within the T-box protein both in humans (712 
amino acids) and mouse (711 amino acids). 
 Similar to Tbx3, Tbx2 also function as a transcriptional repressor (Carreira et al., 
1998; Sinha et al., 2000). Recent advances in proteomics have identified two separate 
repression domains for Tbx2 (Paxton et al., 2002). Along with a carboxy terminal 
repression domain located between amino acids 529 and 573, a novel amino-terminal 
repression domain between amino acids 1 and 53 have been identified (Paxton et al., 
2002). Further studies by Paxton and coworkers found that the carboxy terminal 
repression domain by itself was not sufficient to produce the repressor activity of Tbx2 
(Paxton et al., 2002). Deletion of both the repression domains completely abolished the 
repressor activity of Tbx2, suggesting that amino terminal repression domain play an 
important role in mediating the repressor activity of Tbx2 on target genes (Paxton et al., 
2002). Besides these, a weak activation domain has also been identified in Tbx2. 
Because of the presence of both activation and repressor domains, Tbx2 protein is 
suggested to play multiple specific roles based on the species and cell lines. For 
instance, over expression of Tbx2 increased the expression of type 1 collagen in NIH 
3T3 fibroblasts but decreased col-1expression in rat ROS 17/2.8 osteoblast cell line 
(Chen et al., 2001). In most research carried out to date, Tbx2 primarily acts as a 
transcriptional repressor. Further studies will help to elucidate the specific role of the 
activation and repression domains of Tbx2 protein. 
Functions of Tbx2 
Most studies demonstrate that Tbx2 is expressed primarily during embryonic 
development both in mouse and humans. It is expressed in mouse and human heart, 
lung, kidney, ovary, and bone (Campbell et al., 1995; Law et al., 1995). Transgenic 
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mouse models were created to investigate the specific role of Tbx2 during embryonic 
development. A homozygous mutant for Tbx2 is embryonically lethal in mice due to 
cardiac insufficiency whereas heterozygous mutants are normal (Plageman and  Yutzey, 
2005).  
Role of Tbx2 in cardiac development 
 To date, the function of Tbx2 has only been identified in a few tissues, although it 
is expressed in a wide variety of tissues. In particular, the role of Tbx2 has been 
extensively studied during heart development. It is involved in the proliferation and 
compartmentalization of the developing heart (Harrelson et al., 2004).  Tbx2 is 
expressed as early as 8 days post coitum in the myocardium of the developing mouse 
heart. Many studies demonstrate that Tbx2 may be a downstream target of BMP 
signaling pathways that are important during the development of non chamber 
myocardium (Zhang and  Bradley, 1996). Recent studies demonstrate that Tbx2 along 
with Tbx3 represses the differentiation and formation of cardiac chambers (Christoffels 
et al., 2004) where as Tbx5 and Tbx20 positively regulate the formation of chamber 
myocardium (Cai et al., 2005). This in fact suggests that Tbx2 and Tbx3 may have 
similar function in cardiac tissue and other tissues. 
Role of Tbx2 in mammary development 
 Furthermore, recent studies suggest a role of Tbx2 along with Tbx3 during 
mammary gland development both in humans and mice (Rowley et al., 2004). Tbx3 is 
specifically expressed in the epithelial cells, while Tbx2 is expressed in the underlying 
mesodermal cells of a mammary placode (Rowley et al., 2004). The importance of Tbx3 
on mammary gland was demonstrated by developing a Tbx3 knockout mouse. 
Heterozygous mice showed mammary hypoplasia and abnormalities of nipples, whereas 
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homozygous mice did not develop mammary glands (Davenport et al., 2003a). However, 
the role of Tbx2 during the development of mammary glands is poorly understood with 
comparison to Tbx3. The role of Tbx2 along with Tbx3 was supposedly brought into 
attention when double heterozygous mice for Tbx2 and Tbx3 showed severe 
deficiencies in the formation of mammary placodes than Tbx3 single heterozygote mice 
(Jerome-Majewska et al., 2005). 
Role of Tbx2 in brain, eye and melanocyte development 
In vitro and in vivo studies suggest a role of Tbx2 during brain development, 
specifically the hypothalamus. The evidence for this suggestion arises from the 
interaction of Tbx2 with sonic hedgehog (Shh) in ventral tubero-mammillary cells (a 
subset of hypothalamic cells) (Manning et al., 2006). Besides hypothalamus, Tbx2 is 
also involved in embryonic development of eye and skin. Tbx2 along with other Tbx 
members (Tbx3 and Tbx5) are differentially expressed in the neural retina (Behesti et al., 
2006). Many studies using mouse embryo cultures reveal that these Tbx genes (Tbx2, 
Tbx3 and Tbx5) regulate the embryonic development of eye via BMP4 signaling (Behesti 
et al., 2006). They also reported that homozygous mutant mouse embryos show a 
reduced retinal volume, delayed optic vesicle invagination ultimately leading to small and 
abnormal optic cups. Tbx2 is also expressed in several melanocyte and melanoma cell 
lines but not in pre-melanoblasts (Carreira et al., 1998; Carreira et al., 2000). The role of 
Tbx2 in melanocyte was demonstrated by the interaction of MITF (microphthalamia 
associated transcription factor) with Tbx2. MITF is a key regulator of melanocyte 
proliferation, differentiation and apoptosis (Levy et al., 2006). MITF binds to the Tbx2 
promoter and activates the expression of Tbx2 suggesting a specific role of Tbx2 in 
melanocytes (Carreira et al., 2000).  
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Role of Tbx2 in cell cycle regulation 
 Besides the role of Tbx2 during embryonic development in different tissues 
described above, recent advances in molecular biology and genetics reveal a potential 
role for Tbx2 in cell cycle regulation and cancer. The expression of Tbx2 along with a 
closely related factor, Tbx3, was upregulated in several cancers including breast (Fan et 
al., 2004), pancreatic (Mahlamaki et al., 2002), melanoma (Vance et al., 2005), liver 
(Renard et al., 2007) and bladder (Ito et al., 2005).  The upregulation of Tbx2 in these 
cancers is explained by the fact that it functions as an immortalizing gene and enables 
the cells to bypass senescence (Dobrzycka et al., 2006). Tbx2 along with Tbx3 
suppresses the expression of p19ARF, a tumor suppressor, and promotes the bypass of 
senescence through inactivation of p53 pathway (Dobrzycka et al., 2006). Another 
explanation for the tumorigenic potential of Tbx2 was put forward by Davis and 
coworkers in 2008 (Davis et al., 2008). They proposed that Tbx2 may contribute to 
oncogenesis through bypassing cell cycle check points (Davis et al., 2008). Similarity in 
the functions of Tbx2 and Tbx3 in cell cycle regulation suggests that Tbx2 and Tbx3 may 
have overlapping functions in different tissues. 
Role of Tbx2 in skeletal development 
 Tbx2 along with other Tbx genes (Tbx3, Tbx4 and Tbx5) is expressed in mouse 
embryonic limb buds. Besides mice, the expression of Tbx2 has been extensively 
studied in chicks (Isaac et al., 1998). The spatial and temporal expression of Tbx2 along 
with Tbx3 is very similar in the forelimb and hindlimb buds of mouse and chicks (Gibson-
Brown et al., 1996b; Gibson-Brown et al., 1998). Tbx2 and Tbx3 are required for the 
identity of digit III and IV. Recent advances in the identification of different signaling 
pathways further strengthen the potential role of Tbx2 during limb development. For 
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instance, Shh pathway, involved in the determination of cell fate determination, 
embryonic patterning and organogenesis during early vertebrate development, is 
regulated by the expression of Tbx2 and Tbx3 within the posterior limb bud (Suzuki et 
al., 2004; Nissim et al., 2007).  
Besides the role of Tbx2 during early embryonic limb bud development, recent 
studies in vitro suggest a potential role of Tbx2 during bone development. It was 
demonstrated that Tbx2 is expressed in mouse hypertrophic chondrocytes, periosteal 
osteocytes and osteoblasts (Chen et al., 2001). Furthermore, microarray analysis of 
Tbx2 directed gene expression in NIH3T3 cells, a fibroblast cell line, showed that among 
8734 genes, 107 genes were upregulated and 66 genes were down-regulated by two 
fold or greater. The over expression of Tbx2 in NIH3T3 cells increased the expression of 
several genes [pleiotrophin (osf-1), osteoblast-specific factor-2(osf-2) and collagen type 
1α] that are involved in osteoblastic or chondrocytic lineage (Chen et al., 2001). They 
also carried out transfection experiments with sense and anti-senseTbx2 in a rat 
osteosarcoma cell line (ROS 17/2.8) further suggesting that Tbx2 could potentially be 
involved during bone development (Chen et al., 2001). Specifically, osteoblast specific 
factor 2 (osf-2) was downregulated in ROS 17/2.8 cells transfected with antisense Tbx2 
whereas osf-2 was upregulted in cells transfected with sense Tbx2. In addition, recent 
studies demonstrate that Tbx2 regulates the expression of Connexin 43 (Cx43) in 
osteoblast-like cells (Chen et al., 2004). Cx43 is a gap junction protein found in neural 
crest cells, myocytes, osteoblasts and many other tissues. Cx43 plays an essential role 
in cell-cell communication and is the predominant gap junction protein found in bone and 
plays critical role in normal ossification and osteoblast function (Lecanda et al., 2000).  
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These studies described above prove that Tbx2 is closely related to Tbx3 with 
90% homology in sequence and is functionally similar to Tbx3 in cardiac development 
(Christoffels et al., 2004) and cell cycle regulation (Dobrzycka et al., 2006). Both Tbx2 
and Tbx3 are transcriptional repressors and regulate various stages during 
development. Recent studies have proved the important roles of Tbx3 during postnatal 
bone development (Govoni et al., 2006; Govoni et al., 2009). Identification of such novel 
transcription factors and their role in osteoblast function will provide a better 
understanding of the bone formation process which would further aid in the development 
of potential medical therapeutics for the prevention or treatment of osteoporosis or other 
bone related diseases. To date, there has been neither in vitro nor in vivo data on the 
role of Tbx2 during post natal bone development. Based on the close homology of Tbx2 
and Tbx3, functional similarity of Tbx3 and Tbx2 in different tissues, regulation of 
osteoblast function by Tbx3, and the role of Tbx3 and Tbx2 in embryonic limb bud 
development, we have developed the following hypothesis. 
HYPOTHESIS  
We hypothesize that Tbx2 is an important transcriptional regulator of osteoblast 
function (proliferation and differentiation). 
AIMS 
1. To transfect and knockdown the expression of Tbx2 in MC3T3-E1 (a mouse 
preosteoblast cell line) using small interference RNA (siRNA). 
2. To evaluate the role of Tbx2 in osteoblast proliferation determined by changes in 
cell number and DNA synthesis. 
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3. To evaluate the role of Tbx2 in osteoblast differentiation determined by changes 
in alkaline phosphatase (ALP) activity. 
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MATERIALS AND METHODS 
Cell culture 
The murine preosteoblast-like cell line (MC3T3-E1) was purchased from 
American Type Culture Association (ATCC), Manassas, VA. The media used for the cell 
culture was α-minimal essential medium (α-MEM; invitrogen, cat. no.12571-049) 
containing 10% calf serum (CS; Thermo Scientific, cat. no. SH30072.03) and 1% 
penicillin–streptomycin (PS). The murine bone marrow stromal cells (BMSC) were 
maintained in α-minimal essential medium (α-MEM) containing 10% fetal bovine serum 
(FBS; Thermo Scientific, cat. no. SH30910.03) and 1% PS. The cell culture media 
containing α-MEM + 10% CS without antibiotics were used to plate the cells the day 
before transfection. The cells were maintained at 37⁰C in a humidified atmosphere of 5% 
CO2 and 95% air with media being changed in every 2 to 3 days. Cultures at 
approximately at 70% to 80% confluence were harvested with diluted trypsin-EDTA (0.5 
% trypsin-EDTA). The cells were passaged at least once after thawing and then used for 
each experiment mentioned below (Appendix Section I). 
Isolation of mouse bone marrow stromal cells  
 The mouse BMSC were isolated from 4 to 6 week old mice as previously 
described (Govoni et al., 2006) and plated at a density of 20 X 106 cells per 120 mm petri 
dish. The media used for the maintenance of the mouse BMSC contained α-MEM with 
10% FBS and 1% PS. The cells were allowed to adhere to the plate for 5 to 7 days 
during which 3 mL of the media was added to each plate. Once most of the BMSC 
adhered to the bottom of the plate (approximately 6 days), media was changed every 
three days until the cells reached 70% confluent.  The confluent plates were then used 
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for protein extraction. The details of protein extraction are described in the following 
sections.  
siRNA transfection 
The MC3T3-E1 cells were transfected with siRNA for mouse Tbx2 and 
scrambled negative control (NC siRNA) purchased from Dharmacon (Tbx2 siRNA: 
siGENOME SMART pool, cat. no. M-048790-01; NC siRNA: siGENOME Non-Targeting 
siRNA Pool #2, cat. no. D-001206-14-05). The cells were transfected using 
Lipofectamine 2000 (invitrogen, cat. no. 11668-019) according to the manufacturer’s 
instructions. The transfection conditions were optimized by using a siGLO Red 
transfection indicator (Dharmacon, cat. no. D-001630-02-05). Different concentrations of 
siGLO red/well (16.5, 33, and 66 nM) and Lipofectamine 2000/well (0.5, 1, and 1.5 µL) 
were selected to optimize the transfection efficiency.  24 hr after the transfection, the 
number of fluorescent cells versus non-fluorescent cells were examined. After the 
transfection conditions were optimized, the transfections were performed using Tbx2 
siRNA and NC siRNA. Appropriate controls were used for these experiments. The 
MC3T3-E1 cells with Lipofectamine 2000 was used as a control to substract any 
cytotoxic effect of Lipofectamine 2000. MC3T3-E1 cells transfected with Lipofectamine 
2000 and NC siRNA was another control to substract any effect of siRNA on cell 
proliferation. All data presented are compared with the NC siRNA control samples. 
Briefly, the cells were plated at a density of 2,000 cells/well for osteoblast proliferation, 
5,000 cells/well for osteoblast differentiation in 96-well plates and 70,000 cells/well for 
RNA extraction in 6-well plates. After 24 hrs, the cells were transfected with 66 nM 
siRNA and Lipofectamine 2000 (0.25 µL/well for 96-well plate, 1 µL/well for 24-well plate, 
and 5 µL/well for 6-well plate). The cells were either transfected with Tbx2 siRNA or NC 
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siRNA that served as the negative control. The amount of siRNA and the lipofectamine 
were diluted in Opti-MEM I Reduced Serum Medium (invitrogen, cat. no. 31985-062). 
After the 5 min of incubation, the diluted siRNA was combined with the diluted 
Lipofectamine 2000, mixed gently and incubated for 25 min at room temperature. Then, 
the siRNA-Lipofectamine 2000 complexes were added to each well containing the cells 
and incubated at 37⁰C for 24 hr (Appendix Section II).  
RNA extraction 
The cells were plated at a density of 70,000 cells/well in a 96 well plate.The 
following day, the cells were transfected with siRNA (Tbx2 siRNA or NCsiRNA). 24 hr 
after transfection, the media was removed from the wells, the cells were rinsed with PBS 
twice, and 1 mL of TRI reagent (Sigma Aldrich, cat. no. T9424-200) was added. The 
cells were scraped and transferred to a microcentrifuge tube, vortexed and incubated for 
5 min at room temperature. This was followed by the addition of one-fifth volume of 
>99% chloroform (Sigma Aldrich, cat. no. C2432-500) mixed, and incubated for 2 to 3 
min at room temperature. After the incubation, the tubes were centrifuged at 12,000 X g 
for 15 min at room temperature. The aqueous clear supernatent phase was carefully 
transferred to a new microcentrifuge tube. Thereafter, RNA was extracted using Rneasy 
Mini Kit (Qiagen, cat.no. 74104) according to the manufacturer’s instructions. The total 
RNA was quantified by using a NanoDrop spectrophotometer (Thermo Scientific, 
Wilmington, DE). Following extraction, the residual DNA was removed from RNA 
samples by a 30 min digestion at 37⁰C with DNase using a DNA-free kit (TURBO DNA-
free, Ambion, cat. no. AM1907). The RNA quality was determined using Experion 
Automated Electrophoresis Station (Bio-Rad, Hercules, CA). (Appendix Section III)  
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Reverse transcription (RT)-PCR 
Each RNA sample was diluted to 300 ng/10 µL for the RT-PCR. The reverse 
transcription was performed under standard conditions with SuperScript II reverse 
transcriptase (Invitrogen, cat. no. 18064-014) and Oligo (dT) primers (Ambion, cat.no. 
5730G) in a 20 µL final volume. Briefly, 1 µL of Oligo (dT) primers was incubated with 10 
µL of the 300 ng RNA sample at 70⁰C for 10 min in the S1000 Thermo Cycler (Bio-Rad, 
Hercules, CA) followed by the addition of the master mix containing the dNTP, DTT and 
SuperScript II (Invitrogen, cat. no. 18064-014). Thereafter the reaction conditions were 
37⁰C for 3 min, 42⁰C for 60 min, 4⁰C for 3 min, and 90⁰C for 2 and ½ min. Once the 
reactions were complete, 80 µL of nuclease free water was added to the samples. 
(Appendix Section IV, V and VI)  
Real-time RT-PCR 
Quantitative real-time RT-PCR analysis was used to determine the expression 
levels of Tbx2, Tbx3, and PPIA (peptidylprolyl isomerase A; endogeneous control). Real-
time RT-PCR was performed using Power SYBR Green Master Mix (Applied 
Biosystems, cat. no. 4367659) and 7500 Fast Real-Time PCR system (Applied 
Biosystems, Foster city, CA). Specifically, 20 µL of the reaction was loaded onto a Fast 
Optical 96 well reaction plate (Applied Biosystems, cat. no. 4346906). Each reaction 
contained 10 µL of 2X Power SYBR Green Master Mix, 1 µL each of 10mM of forward 
and reverse primer, 3 µL of nuclease free water, and 5 µL of cDNA. The PCR conditions 
were 50⁰C for 20 s, 95⁰C for 10 min, 95⁰C for 15 s, 60⁰C for 1 min, 95⁰C for 15 s, 60⁰C 
for 1 min, 95⁰C for 30 s, and 60⁰C for 15 s. The ∆CT values were determined by 
subtracting the CT value for the control gene from the CT value for the gene of interest. 
Once the ∆CT was determined for the control and the treatment group, ∆∆CT was 
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calculated to express the relative quanitificationof gene expression (Govoni et al., 2006). 
The primers used to amplify mouse Tbx2 were forward: 5’ -TGA AGC TCC CAT ACA 
GCA CCT T -3’, reverse: 5’ –TTG TCG ATC TTC AGC TGT GTA ATC T -3’, PPIA; 
forward: 5’ –TCC TGG ACC CAA AAC GCT CC -3’, reverse: 5’ –CCA TGG CAA ATG 
CTG GAC CA -3’, Tbx3; forward 5’ –TTC CTA CCT CAC CGG GCG -3’, reverse: 5’ –
CCG TTG GGA GGC AGC GT -3’. (Appendix Section VIII) 
Western Blot  
Preparation of whole cell lysate  
 
Cells were seeded at a density of 70,000 cells/well in a 6-well plate. After 24 hr, 
the cells were transfected with siRNA. Forty eight hr after transfection, they were 
scraped into ice-cold phosphate-buffered saline (PBS, pH7.4) and centrifuged at 12,000 
X RPM for 5 min. The pellet was lysed with 25 µL of modified RIPA lysis buffer 
(TEKnova, cat. no. R3792). The modified RIPA buffer was prepared by the adding 10 µL 
of the 100 X Halt protease inhibitor cocktail (PIC; Sigma Aldrich, cat. no. 1862209).Then 
the lysate was incubated on ice for 30 min followed by centrifugation at 12,000 X RPM 
for 5 min at 4⁰C. The supernatent was transferred to a pre-cooled microcentrifuge tube 
and stored at -80⁰C until used. 
Preparation of whole tissue lysate 
The bone, lung and heart were isolated from a 3 to 4 week old mouse and snap 
frozen in liquid nitrogen. A mortar and pestle was used to grind the tissues in the liquid 
nitrogen. This was followed by the addition of 3 mL RIPA lysis buffer, mixed properly and 
transferred to a microcentrifuge tube. The lysate was then incubated on ice for 1 hr 
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followed by centrifugation at 12,000 X RPM for 5 min at 4⁰C. The supernatent was 
transferred to a pre-cooled microcentrifuge tube and stored at -80⁰C until used. 
Protein estimation 
The protein concentration was estimated using DC protein assay (Bio-Rad, 
cat.no. 500-0114). Bovine serum albumin (BSA; Sigma Aldrich, cat no. A7888-100G) 
was used as the standard. Specifically, different dilutions of BSA standards ranging from 
0.125 mg/mL to 2 mg/mL were prepared. RIPA buffer with PIC was used as the diluent 
to prepare these BSA standards. Additionally, the protein samples for the estimation 
were also diluted in a ratio of 1:5 using the same diluent. Then 5 µl of the standards and 
the samples were pipetted into a clean 96-well plate followed by the addition of reagent 
A and reagent B. After 15 min of incubation at room temperature, the absorbances were 
read at 750 nm in the plate reader (Synergy 2, BioTek, VT, USA). 
SDS-PAGE and immunoblotting 
Equal amounts of protein (40 µg) were placed in sample buffer (63 mM Tris HCl, 
pH 6.8, 2 mM EDTA, 10 mM β-mercaptoethanol, 10% glcerol, 2% SDS, and 0.0025% 
Bromophenol blue) and heated to 65⁰C for 10 min. The denatured proteins were 
vortexed, briefly centrifuged and loaded onto a 10% sodium dodecyl sulphate-
polyarylamide gel (SDS-PAGE) along with a SDS-PAGE protein standard (Precision 
plus protein standards kaleidoscope, Bio-Rad, cat.no.161-0375). For a better separation 
of proteins, the gel was run at 100 volts for 170 min at room temperature. After this, the 
proteins were transferred to a nitrocellulose membrane at 100 volts for 150 min. To 
confirm the complete transfer of proteins from the gel onto the membrane, the gel was 
stained with Coomasie blue solution (0.5%; Fisher scientific, cat. no. D203010) for 30 
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minutes at room temperature and the blot was stained with Ponceau S solution (0.1%; 
Fischer Scientific, cat. no. BP103-10). The blot was destained by a thorough rinsing with 
Tris-buffered saline tween-20 (TBST). The membrane was blocked in 5% non fat milk in 
TBST for 2 hr at room temperature. After washing with TBST, the membrane was 
probed with rabbit anti-Tbx2 antibody (1:500; abcam, cat. no. ab33298) overnight at 4⁰C. 
The following day, the membrane was washed thrice with TBST and incubated with a 
horseradish peroxidase conjugated anti-rabbit antibody (Sigma Aldrich, ca. no. A0545) 
for 60 min at room temperature. The excess antibody was rinsed off by washing with 
TBST three times. The Tbx2 protein was then visualized using Super Signal West Pico 
Chemiluminescent Substrate (Thermo scientific, cat. no. 34077). For reblotting, the 
membrane was stripped at 55⁰C for 30 min in stripping buffer [62.5 mM tris HCl (pH 6.8), 
2% SDS, and 0.7% β-mercaptoethanol]. The blot was then washed thrice in TBST with 
10 min interval followed by blocking with 5% non fat milk in TBST for 60 min at room 
temperature. After blocking, the membrane was reprobed with rabbit anti- β-actin 
antibody (1:500, Sigma Aldrich cat. no. A2066) overnight at 4⁰C and served as the 
loading control. On the next day, the membrane was washed with TBST, followed by 
incubation with horseradish peroxidase conjugated anti-rabbit antibody (Sigma Aldrich, 
ca. no. A0545) for 60 min at room temperature, and visualized as described above. 
(Appendix Section IX)  
Cell proliferation assay 
alamarBlue assay 
 The alamarBlue assay is used to determine the cell number. MC3T3-E1 cells 
were plated at a density of 2,000 cells/well in a 96-well plate in culture media (α-MEM 
containing 10 % CS). A day after, the cells were transfected with siRNA (negative control 
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siRNA or Tbx2siRNA). 24 hr after transfection, the cells were deprived of serum for 
another 24 hr, and then treated with either 0.1% BSA or 1% CS. The alamarBlue assay 
was used to determine the cell number 48 hr after treatment. In particular, the cells were 
rinsed twice with 100 µL of PBS followed by the addition of diluted alamarBlue indicator 
(invitrogen, cat. no. DAL1025). The alamarBlue indiactor was diluted in a ratio of 1:10 
using α-MEM. After 4 hr of incubation at 37°C, the fluorescence was determined using a 
fluorescent plate reader (Synergy 2, BioTek) at 540/35 X 600/40 nm with sensitivity set 
at 54. (Appendix Section X)  
5-bromo-2’deoxyuridine (BrdU) assay 
BrdU assay is a chemiluminescent assay for the quantification of cell 
proliferation, based on the measurement of BrdU incorporation during DNA synthesis 
(Roche Applied Science, cat. no. 11669915001). Similar to the alamarBlue assay, the 
cells were plated at a density of 2,000 cells/well in a 96-well plate. After 24 hr of 
incubation, the cells were transfected with siRNA. 24 hr after transfection, the cells were 
deprived of serum for another 24 hr, and then treated with either BSA or 1% CS. The 
BrdU assay was performed to determine the DNA synthesis 48 hr after treatment. 
Specifically, the cells were incubated with BrdU labelling solution at a concentration of 
10 µL/well for 2hrs at 37°C. After the incubation, the labelling solution was 
removed.Then the cells were fixed and DNA was denatured. This was followed by the 
addition of anti-BrdU-POD antibody (100uL/well) which binds to the BrdU incorporated in 
the newly synthesized DNA. The excess antibody was removed. 100 µL/well of the 
substrate solution was added to each well and incubated for 5 min at room temperature. 
The chemiluminescence was detected using the plate reader (Synergy 2, BioTek, VT, 
USA). (Appendix Section XI)  
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Cell differentiation assay 
Alkaline Phosphatase (ALP) activity 
The cells were plated at a density of 5,000 cells/well in a 96-well plate. On the 
next day, the cells were transfected with siRNA (NCsiRNA or Tbx2siRNA). After 24 hr of 
incubation at 37⁰C, the cells were deprived of serum. The media used for serum 
deprivation was α-MEM containing 0.1% BSA, 1% PS, 50 µg/mL ascorbic acid (Sigma 
Aldrich, cat. no. A8960), and 10mM of β-glycerophophate (Sigma Aldrich, cat. no. 
G9891). Twenty four  hr later, the cells were treated with either 0.1% BSA or human 
bone morphogenetic protein 2 (hBMP-2) at a concentration of 30 ng/mL and incubated 
for 72 hr at 37⁰C. The ALP activity was measured as previously described (Govoni et al., 
2008). Briefly, the cells were washed with PBS two times, permealized with 100 µL of 
0.1% triton followed by a freeze thaw procedure. Of the 100 µL, 40 µL and 20 µL of the 
lysate was transferred to a new 96-well plate for determining the ALP activity and protein 
concentration, repsectively. 200 µL of the ALP substrate, p-Nitrophenyl phosphate 
(pNPP; Sigma Aldrich, cat. no. P7998-100), was added to each well. The absorbance 
was read immediately (0 hr) and after 5 hr of substrate addition at 405 nm using the 
plate reader (Synergy 2, BioTek, VT, USA). The protein concentration was measured by 
usingthe Quick Start Bradford Protein asay (Bio-Rad, cat. no. 500-0205) and bovine 
serum albumin (BSA, Sigma Aldrich, cat no. A7888-100G) that served as the protein 
standard. The ALP activity was standardized to the cellular protein content. (Appendix 
Section XII). 
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Statistical analysis 
Data were analyzed by analysis of variance (ANOVA) and/or student’s t-test 
where appropriate. Data were analyzed by using SAS 9.2 software (SAS Institute Inc., 
Cary, NC, U.S.A.). Data are presented as mean + SE and a significant difference was 
determined at P ≤ 0.05. 
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RESULTS 
Efficiency of  siRNA transfection  
 To determine the efficiency of transfection, MC3T3-E1 cells were transfected with 
siGLO red transfection indicator, a negative control (NC) siRNA at 16.5, 33, and 66 nM 
and Lipofectamine 2000 transfection reagent at 0.5, 1.0, and 1.5 µL, followed by the 
quantification of fluorescent cells (Figure 2). Overall, the cells transfected with 16.5 nM 
and 66 nM of siRNA had the lowest and greatest transfection efficiency, respectively (P 
< 0.001; Figure 3). Specifically, the cells transfected with 16.5 nM of siRNA  and 0.5, 1.0, 
and 1.5 µL  of Lipofectamine 2000 had 30, 43 and 55 % of cells transfected with siRNA, 
respectively (P < 0.001). Similarly, the cells transfected with 33 nM of siRNA  and 0.5, 
1.0, and 1.5 µL  of Lipofectamine 2000 had 38, 75 and 74 % of cells transfected with 
siRNA, respectively (P < 0.001). The cells transfected with 66 nM of siRNA  and 0.5 µL, 
1.0 µL, and 1.5 µL  of Lipofectamine 2000 had 54, 83 and 86 % of cells transfected with 
siRNA,  respectively (Figure 3). We determined the greatest transfection efficiency with 
66 nM of siGLO red and 1.5 µL of Lipofectamine 2000. We did not detect any significant 
difference (P < 0.596) in the efficieny of transfection when treated with 1.0 µL or 1.5 µL 
of Lipofectamine 2000/well and 66 nM of siGLO red. Since the Lipofectamine 2000 is 
slightly cytotoxic, we decided to use 1.0 µL of Lipofectamine 2000/well for transfection. 
Thus, it was deduced through optimization to use 66 nM of siRNA with 1.0 µL of 
Lipofectamine 2000 per well for our experiments. 
Knockdown of  Tbx2 expression using siRNA 
 The mRNA expression of Tbx2 was reduced by 81 + 2 and 78 + 2 %  after 24 
and 48 hr of transfection, respectively  when compared to the control (P < 0.015; Figure 
4). To determine if the knockdown of Tbx2 altered Tbx3 expression, the mRNA 
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expression of Tbx3 was also determined 24 and 48 hr after transfection with Tbx2 
siRNA. Surprisingly, the expression of Tbx3 was reduced by 40 + 2 % at 24 and 48 hr 
after transfection when compared to the control (P < 0.015; Figure 5). 
Western blot analysis 
To confirm the knockdown of Tbx2 protein, western blot analysis was performed 
using Tbx2 specific antibody. The whole cell lysate proteins were extracted from the 
MC3T3-E1 cells after transfection with siRNA (Tbx2 siRNA and NC siRNA). Surprisingly, 
we did not detect significant amounts of Tbx2 protein in the NC siRNA and Tbx2 siRNA 
transfected samples (data not shown). In addition, we also did not detect Tbx2 protein in 
the normal nontransfected MC3T3-E1 cells (Figure 6 A). To confirm that the antibody 
used for the western blot was effective, we extracted protein from mouse lung, which 
has been shown to have high expression of Tbx2 (Chapman et al., 1996a). We were 
able to detect Tbx2 protein in mouse lung at 75 kDa, the expected molecular size for this 
protein (Figure 6 A).To determine if the lack of Tbx2 protein expression in MC3T3-E1 
cells was specific to the cell line, we looked at the Tbx2 protein expression in mouse 
bone tissue lysate, mouse BMSC, and human osteosarcoma cell line (Saos-2; Figure 6 
A and B). We did not detect Tbx2 protein in mouse bone tissue lysate and BMSC (Figure 
6 A). However, a band at approximately 100 kDa was observed in Saos-2 cells (Figure 6 
B). To confirm that 75 kDa band in MC3T3-E1  cells and 100 kDa band in Saos-2 cells 
were indeed Tbx2, we performed western blot with Tbx2 blocking peptide. The blocking 
peptide successfully removed the 75 and 100 kDa bands (Figure 7), thus confirming that 
the bands were indeeed Tbx2. 
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Role of Tbx2 in osteoblast function 
 We did not observe a significant effect (P > 0.29) of knockdown of Tbx2 mRNA 
expression on osteoblast cell number (Figure 8) and DNA synthesis (Figure 9) in the 
presence or absence of serum. Similarly we did not observe a significant change (P > 
0.255)  in ALP activity both in the presence or absence of BMP-2 in cells transfected 
with Tbx2 siRNA (Figure 10). 
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Figure Legends 
Figure 2. Optimization of siRNA transfection. Cells were transfected with various 
concentrations of siGLO red transfection indicator (16.5, 33, and 66 nM) and 
Lipofectamine 2000 (lipo; 0.5, 1.0, and 1.5 µL). Data are presented as mean + SE. Bars 
with different letters are significantly different at P < 0.001. n = 4/treatment. 
 
Figure 3. Transfection efficiency of MC3T3-E1 cells using 66 nM of siGLO red siRNA 
and 1.0 µL of Lipofectamine 2000. The efficency was determined by the number of 
fluorescent cells vs. non-fluorescent cells. Each image is a representative of an 
experiment which included 4 plates/treatment and had 86 % of cells transfected with 
siRNA. 
 
Figure 4. Knockdown of Tbx2 expression. MC3T3-E1 cells were transfected with 66 nM 
Tbx2 siRNA or negative control siRNA (NC siRNA; control) with n = 4/treatment and the 
mRNA  expression were determined by real-time RT-PCR analysis 24 and 48 hr after 
transfection.  Data are presented as mean + SE and expressed as % of control. * 
indicates a significant difference at P < 0.015.  
 
Figure 5. Expression of Tbx3 in cells transfected with Tbx2 siRNA. MC3T3-E1 cells were 
transfected with 66 nM Tbx2 siRNA or negative control siRNA (NC siRNA; control) with n 
= 4/treatment and the mRNA expression were determined by real-time RT-PCR analysis 
24 and 48 hr after transfection. Data are presented as mean + SE and expressed as % 
of control. * indicates a significant difference at P < 0.015.  
 
Figure 6. Tbx2 protein expression in various tissues and cell lines. A) Western blot 
analysis was used to detect Tbx2 protein in mouse lung, mouse bone marrow stromal 
cells (BMSC), MC3T3-E1 cells and Saos-2 cells. B) Western blot analysis was used to 
detect Tbx2 protein in mouse lung, MC3T3-E1 cells, and Saos-2 cells. β-actin served as 
loading control for all the western blot analysis. 
 
Figure 7. Confirmation of Tbx2 protein in mouse and human samples.The 100 kDa band 
in Saos-2 cells and 75 kDa band in mouse lung tissue lysate were confirmed as Tbx2 
protein by peptide neutralisation.  
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Figure 8. Role of Tbx2 in osteoblast cell number. Osteoblast cell number was 
determined by alamarBlue assay. The MC3T3-E1 cells were transfected with 66 nM 
Tbx2 siRNA and negative control siRNA (control) in the absence (0.1 % BSA) or 
presence (0.1 % BSA + 1 % CS) of calf serum. Data are presented as mean + SE and 
expressed as % of control. n = 4/treatment.  
 
Figure 9. Role of Tbx2 in osteoblast DNA synthesis. DNA synthesis was determined by 
BrdU assay. The MC3T3-E1 cells were transfected with 66 nM Tbx2 siRNA and negative 
control siRNA (control) in the absence (0.1 % BSA) or presence (0.1 % BSA + 1 % CS) 
of calf serum. Data are presented as mean + SE and expressed as % of control. n = 
4/treatment. 
 
Figure 10. Role of Tbx2 in osteoblast differentiation. Osteoblast differentiation was 
determined by ALP activity and corrected for protein. The MC3T3-E1 cells were 
transfected with 66 nM Tbx2 siRNA and negative control siRNA (control) in the presence 
or absence of BMP-2 at a concentration of 30 ng/mL. Data are presented as mean + SE 
and expressed as % of control. n = 4/treatment. 
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DISCUSSION 
The process of bone formation is very complex and tightly regulated by 
hormones, growth factors and transcription factors. With the recent advances in mouse 
and human genetic information, studies have led to the identification of novel 
transcription factors that regulate bone formation. Identification of these novel 
transcription factors will provide a better understanding of the bone formation process 
and will ultimately aid in the development of potential therapies for the prevention and/or 
treatment of osteoporosis or other bone related diseases. 
 The Tbx family is one among the novel transcription factors that has very 
recently been shown to regulate embryonic limb development and osteoblast function. 
Specifically Tbx2, Tbx3, Tbx4, and Tbx5 are highly expressed in the limb buds and 
extensively studied to understand their role during embryonic skeletal development 
(Chapman et al., 1996; Candille et al., 2004). Very recent studies demonstrate that Tbx 
transcription factors are also expressed postnatally. In particular, Tbx3 expressed in 
adult mouse bone, is regulated by several growth factors and regulates osteoblast 
function (Govoni et al., 2006). A very closely related member to Tbx3 is Tbx2 with 90% 
homology in the mRNA sequence. In addition, both Tbx2 and Tbx3 are transcriptional 
repressors and regulate various stages during embryonic development (Plageman and  
Yutzey, 2005). They are functionally similar in different tissues including embryonic heart 
development (Christoffels et al., 2004), embryonic eye development (Behesti et al., 
2006) and cell cycle regulation (Dobrzycka et al., 2006). As described above, the role of 
Tbx3 in osteoblast function has been well characterized. However, to date there are no 
data available on the role of Tbx2 in osteoblast function during postnatal bone 
development. 
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 Through the use of RNA interference we have attempted to elucidate the 
function of Tbx2 in osteoblast proliferation and differentiation. Based on the knowledge 
that Tbx2 is very closely related to Tbx3 in sequence homology, has overlapping 
functions in embryonic heart, eye development and cell cycle regulation (Christoffels et 
al., 2004; Dobrzycka et al., 2006), we hypothesized  that similar to Tbx3, Tbx2 also 
regulates osteoblast function. For this study, we successfully transfected a murine 
preosteoblast cell line (MC3T3-E1) and knocked down the mRNA expression of Tbx2 
using Tbx2 siRNA and Lipofectamine 2000. Previous studies have successfully used the 
transfection reagent Lipofectamine 2000 to transfect the MC3T3-E1 cells with siRNA 
(Alford et al., 2010). In particular, the concentration of Lipofectamine 2000 used by the 
Alford and coworkers was similar to the concentration used for this study (Alford et al., 
2010). Similarly, Tbx2 siRNA has also been previoulsy used to knockdown the 
expression of Tbx2 in breast cancer cell lines (Redmond et al., 2010). Specifically, they 
knocked down the expression of Tbx2 by more than 90 % at 24 hr after transfection 
(Redmond et al., 2010). This is consistent with our findings that we were able to 
successfully transfect the MC3T3-E1 cell lines and knock down the expression of Tbx2 
by more than 80 % at 24 hr after transfection. 
As described above, Tbx2 is very closely related to Tbx3, sharing 90 % 
homology in sequence and overlapping functions in many tissues. Based on these 
findings, we anticipated that Tbx2 and Tbx3 may have similar expression patterns and 
functions in osteoblasts. A previous study in which Tbx3 was knocked out in mouse 
suggested a compensatory upregulation of Tbx2 with the loss of Tbx3 in embryonic 
heart development (Plageman and  Yutzey, 2005). To determine if the knockdown of 
Tbx2 altered Tbx3 expression, the mRNA expression of Tbx3 was determined in 
MC3T3-E1 cells treated with Tbx2 siRNA. Surprisingly, we observed a significant 
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decrease in the expression of Tbx3 by 40 % in cells transfected with Tbx2 siRNA. 
Although the non-specificity of Tbx2 siRNA used for this study may be a possible 
explanation for reduced Tbx3 expression in MC3T3-E1 cells treated with Tbx2 siRNA, it 
is unlikely. To determine the specificity of Tbx2 siRNA, the four Tbx2 siRNA sequences 
present in the mouse Tbx2 siGENOME smart pool were blasted against the mouse 
genome and the results matched only to the mouse Tbx2 mRNA and were not 
homologous to Tbx3. Hence, the non specificity of Tbx2 siRNA is less likely an 
explanation for the reduced expression of Tbx3 with knock down of Tbx2.  
A biological effect within the cells is more likely an explanation for the reduced 
expression of Tbx3 mRNA in MC3T3-E1 cells transfected with siRNA. Contrary to our 
findings, it has been demonstrated that transfection of a melanoma cell line with Tbx3 
siRNA led to upregulation of Tbx2 suggesting that Tbx3 represses the expression of 
Tbx2 in melanoma cells (Rodriguez et al., 2008). This study suggests that the change in 
Tbx3 mRNA expression may be a biological effect of reduced Tbx2 and substantiates for 
the variation in the expression of Tbx3 and Tbx2 when transfected with siRNA as a 
biological effect. Studies involving Tbx3 deficient mice also demonstrate the variation in 
the expression of Tbx2 (Davenport et al., 2003b; Bakker et al., 2008). Specifically, in situ 
hybridization of the Tbx3 homozygous mutant embryos demonstrated a greatly reduced 
and absence of Tbx2 expression in the posterior margin of the forelimb and hindlimb, 
respectively whereas the expression of Tbx4 and Tbx5 was not altered (Davenport et al., 
2003b). This suggests that knocking down Tbx3 expression reduces the expression of 
Tbx2 in embryonic limb bud. This is similar to our findings where knocking down the 
expression of Tbx2 in a mouse preosteoblast cell line reduced the mRNA expression of 
Tbx3. It is still not clear if the expression of Tbx2 and Tbx3 appear to be dependent on 
each other, however further studies are necessary to elucidate the relative expression of 
67 
 
Tbx2 or Tbx3 within the osteoblast and determine if they are indeed dependent on each 
other. 
Tbx2 is expressed in mouse and human heart, lung, kidney, bone, and mammary 
tissue during embryonic development (Fan et al., 2004; Ito et al., 2005). Although Tbx2 
is expressed in various tissues, the functions of Tbx2 are not yet well understood in 
these tissues. Based on the fact that Tbx2 is widely expressed in several tissues 
including embryonic bone, it is expected that Tbx2 is also expressed in MC3T3-E1 cells, 
a preosteoblast cell line. As predicted, we observed Tbx2 mRNA expression in the 
MC3T3-E1 cells. To further verify the fact the Tbx2 is indeed expressed in the MC3T3-
E1 cells, the two Tbx2 primers used for this study were validated by sequencing the 
PCR product and blasted against the mouse genome. Results of the blast analysis 
matched only to the mouse Tbx2 mRNA. Therefore, it was confirmed that Tbx2 is 
expressed in MC3T3-E1 cells at the mRNA level. 
To confirm the knockdown of Tbx2 at the protein level, whole cell lysate proteins 
were extracted from the siRNA transfected cells and western blot was performed. 
Surprisingly, we could not detect significant amounts of Tbx2 protein in either of the 
siRNA transfected MC3T3-E1 cells (NC siRNA or Tbx2 siRNA) or in non transfected 
MC3T3-E1 cells. Previous studies demonstrate that Tbx2 is highly expressed in mouse 
lung (Chapman et al., 1996a). To confirm that the antibody used for the western blot was 
effective, we extracted mouse lung protein and used it as a positive control. The Tbx2 
protein could be detected in the mouse lung at 75 kDa but not in the MC3T3-E1 cell 
lysate. Furthermore, to validate the lack of Tbx2 protein expression was not specific to 
the cell line, we looked at the expression of Tbx2 protein in mouse BMSC, bone tissue 
lysate, and human osteosarcoma cell line (Saos-2). A previous study demonstrated the 
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presence of Tbx2 protein in many osteosarcoma cell lines including Saos-2, ROS 17/2.8, 
and MG63 (Chen et al., 2001). Similar to their findings, we detected the Tbx2 protein in 
Saos-2 cells but at approximately 100 kDa. The predicted molecular size of Tbx2 protein 
is 75 kDa but our western blot showed an intense band at 100 kDa that was later 
confirmed as Tbx2 protein by the peptide neutralization. It is unclear as to why the Tbx2 
protein was detected in two molecular sizes by western blot analysis. The possible 
explanations for the disparity in molecular size may be due to alternative splicing of Tbx2 
mRNA. Previous studies have demonstrated that alternate splicing can occur in human 
Tbx2 (generally denoted as TBX2) and lead to proteins of varying molecular sizes 
(Campbell et al., 1998). Moreover, in communication with a research lab extensively 
working on Tbx2 in South Africa further substantiated for the band observed at 100kDa 
(Dr. Sharon Prince Lab, Department of Human Biology, University of Cape Town, South 
Africa). Similar to our findings, they also detect the Tbx2 protein at approximately 
100kDa (Abrahams et al., 2008). Although it is unclear as to why two different band 
sizes were obtained for Tbx2, it was confirmed by peptide neutralization that the bands 
observed at 75 kDa in mouse lung and approximately at 100 kDa in Saos-2 cells were 
indeed Tbx2. Further studies on the structure of Tbx2 protein are necessary to address 
the disparity in molecular sizes of Tbx2 protein in western blot analysis. 
We failed to detect Tbx2 protein is not present in detectable amounts in MC3T3-
E1 cells, mouse BMSC, and bone tissue lysate but is detected in Saos-2 cells. This 
finding is consistent with the detection of varying amounts of Tbx2 protein in 
melanocytes (Vance et al., 2005). In particular, it has been demonstrated that the Tbx2 
protein is poorly expressed or absent in both primary human melanocytes and mouse 
melanocyte cell line whereas greatly expressed in melanoma cell lines (Vance et al., 
2005). Very similar to their findings, we could not observe significant amounts of Tbx2 
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protein in mouse BMSC and mouse osteoblast cell line but greatly expressed in Saos-2, 
a human osteosarcoma cell line. Similarly, the expression of Tbx2 is upregulated in 
many cancers, including breast, pancreatic, melanoma, liver, and bladder (Fan et al., 
2004; Ito et al., 2005). Tbx2 along with Tbx3 prevents senescence in these cancer cells 
by a mechanism involving their ability to transcriptionally repress p14ARF, a tumor 
suppressor gene (Lingbeek et al., 2002). This demonstrates that Tbx2 is involved in cell 
cycle regulation suggesting that Tbx2 may be an important regulator of cancer cell 
progression. A better understanding of the upstream and downstream targets for Tbx2 
will provide a better understanding of the upregulation of Tbx2 in several cancerous 
tissues. 
The expression of Tbx2 also varies greatly within a cell type. For instance, the 
expression of Tbx2 at the mRNA level and at the protein level were examined in a 
variety of breast cancer cell lines and it was observed that the Tbx2 protein was 
detected in only three out of eight breast cancer cell lines used for the study (Redmond 
et al., 2010). Similarly, Tbx2 protein was detected in five of the twelve human melanoma 
cell lines examined by Rodriguez and coworkers (Rodriguez et al., 2008). These studies 
suggest that the expression of Tbx2 varies greatly within a cell type. Therefore, the 
selection of a cell line that expresses Tbx2 both at the mRNA and protein level forms the 
basic criterion to study the functional role of Tbx2 within a cell type.  
Thus, our study revealed that there are detectable amounts of Tbx2 expression 
at the mRNA level but Tbx2 protein was not detected in MC3T3-E1 cells. This suggests 
that the Tbx2 mRNA expression profile does not correlate with expression profile of Tbx2 
protein. Similar findings have been observed in many eukaryotic proteomic studies (Gygi 
et al., 1999; Chen et al., 2002). A previous study determined the relationship between 
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mRNA and protein expression levels for 150 genes in the yeast Saccharomyces 
cerevisiae (Gygi et al., 1999). They demonstrated that the quanitification of mRNA is 
insufficient to predict the protein levels within the cell. In particular, they observed that 
the correlation between mRNA and protein expression is greatly reduced in lesser 
abundant proteins when compared to greater abundant proteins (Gygi et al., 1999). This 
suggests the importance of posttranslational mechanisms regulating gene expression 
especially in less abundant proteins. In this context, Tbx2 being a less abundant protein 
can explain for the disparity in the mRNA and protein expression profile. Further studies 
are needed to address this variation in the mRNA and protein expression profile of Tbx2 
in MC3T3-E1 cells. 
Surprisingly, we did not observe any effect of knockdown of Tbx2 on osteoblast 
proliferation and differentiation. Specifically, knocking down the expression of Tbx2 using 
siRNA did not affect the proliferation or differentiation of osteoblasts both in the presence 
or absence of serum. Previous studies have demonstrated the role of Tbx2 in cell cycle 
regulation (Dobrzycka et al., 2006). As described earlier, Tbx2 along with Tbx3 act as 
anti senescence factors in several cancers (Fan et al., 2004; Ito et al., 2005). Bypassing 
the senescence leads to uncontrolled cell proliferation thereby ultimately leading to 
cancer. Additionally Tbx3, closely related to Tbx2 with 90% homology in sequence and 
functional similarity in tissues, has been demonstrated to be an important mediator of 
osteoblast proliferation by Govoni and coworkers in 2006 (Govoni et al., 2006). They 
observed that knocking down the expression of Tbx3 in MC3T3-E1 cells reduced 
osteoblast proliferation both in the presence or absence of serum (Govoni et al., 2006). 
Several other studies have also demonstrated the regulatory effect of Tbx3 on cell 
proliferation. For instance, the proliferation rates of rat bladder hyperplastic epitehlial and 
carcinoma cells are regulated by Tbx3 (Ito et al., 2005). In addition to the role of Tbx3 on 
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osteoblast proliferation, studies have demonstrated that Tbx3 regulates osteoblast 
differentiation (Govoni et al., 2006; Govoni et al., 2009). Specifically, they reported that 
the expression of Tbx3 increased 2 fold during in vitro differentiation of MC3T3-E1 cells. 
In addition, Tbx3 increased the expression of BMP-7 and Wnt3a (Govoni et al., 2006), 
known stimulators of osteoblast differentiation further confirming the fact that Tbx3 
regulates osteoblast differentiation. Based on the close homology in sequence and 
functional similarity of Tbx3 to Tbx2, we hypothesized that Tbx2, like Tbx3 regulates 
osteoblast proliferation and differentiation. However, we could not determine any effect 
of Tbx2 on osteoblast proliferation and differentiation. But this could be due to lack of 
Tbx2 protein in these cells and did not knock it down. 
 Our preliminary results are comparable to previous studies which demonstrate 
that although Tbx2 and Tbx3 are very closely related, they may differ in their expression 
and have distinct roles within a cell type (Rodriguez et al., 2008; Peres et al., 2010). In 
several melanoma cell lines used for the study, no cell lines demonstrated significant 
amounts of both Tbx2 and Tbx3 protein detected by western blot analysis (Rodriguez et 
al., 2008). The cell lines that greatly expressed Tbx3 protein poorly expressed Tbx2 
protein and vice versa suggesting a significant biological function of only one of the two 
(Tbx2 or Tbx3) in melanoma cells. These factors could account for the poor expression 
of Tbx2 protein in MC3T3-E1 cells, where Tbx3 protein is expressed (Govoni et al., 
2006). Very recently, a study demonstrates that Tbx3 and Tbx2 have distinct roles in the 
melanoma and breast cancer cell line (Peres et al., 2010). They report that Tbx2 
promotes cell proliferation and does not affect the cell migration whereas Tbx3 is 
required for tumor formation and cell migration and in fact inhibits cell proliferation 
(Peres et al., 2010). The differential expression and distinct role of Tbx3 and Tbx2 within 
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a cell type suggests that Tbx2 is not an important regulator of osteoblast function like 
Tbx3. 
 To conclude, we transfected and knocked down the expression of Tbx2 in 
MC3T3-E1 cells to evaluate the role of Tbx2 in osteoblast function. We did not determine 
any effect of Tbx2 in osteoblast function including proliferation and differentiation. There 
are two possible explanations for why we did not observe any effect of Tbx2 in 
osteoblast function. Firstly, it is possible that Tbx2 is not required for the osteoblast 
function which is suggested by the absence or poor Tbx2 protein expression in MC3T3-
E1 cells. Secondly, based on little to no Tbx2 protein expression in MC3T3-E1 cells, 
knock down of Tbx2 was not an optimal method to evaluate its role on osteoblast 
proliferation and differentiation. Further studies involving the over expression of Tbx2 in 
MC3T3-E1 cells are needed to better understand the role of Tbx2 on osteoblast function. 
Use of other preosteoblast cell lines that express Tbx2 both at the mRNA and at the 
protein level is an alternate method to elucidate the role of Tbx2 on osteoblast function.  
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APPENDIX 
Section I. Cell culture - maintenance of MC3T3-E1 cell lines 
 
1. Warm the bottles of α-MEM + 10% CS + 1% PS media, PBS, and 50% Trypsin-
EDTA + 50% PBS in water bath at 37°C. Note: Do not place the bottle with Trypsin-
EDTA directly in water. 
2. Wipe down the working area in the hood with a 70% ethanol soaked gauze sponge.  
Spray or wipe the pipette gun and a 50 mL Falcon tube with 70% ethanol and place 
them in the hood. 
3. Wipe the bottles from the water bath with 70% ethanol gauze and place them into the 
hood. 
4. Once all above steps are done remove the cell culture dishes from the incubator and 
place them into the hood. 
5. Tilt the plate of cells.  Using a glass Pasteur pipette and the vacuum pump, remove 
the media from the plate without touching the bottom of plate with the pipette tip.  
6. Tilt the plate and use a transfer pipette to gently add PBS to the plate, from the side 
wall. Then swirl the PBS over the plate to rinse the cells.  
7. Tilt the plate and using a glass Pasteur pipette and the vacuum pump remove the 
PBS from the plate. 
8. Add 50% trypsin-EDTA + 50% PBS directly onto the cells. 
9. Incubate the plate for 3 min at 37°C. 
10. Remove the plate from incubator and place it in the hood. Tilt the plate and with a 
transfer pipette draw up some of the 50% trypsin-EDTA + 50% PBS. Using the liquid 
in the pipette rinse the bottom of plate.  When the cells are detached, use a transfer 
pipette to add α-MEM + 10% CS + 1% PS media to inactivate the trypsin-EDTA. 
11. Keep rinsing the plate with 50% trypsin-EDTA + 50% PBS and α-MEM + 10% CS + 
1% PS media until bottom of the plate has no visible residue. 
12. Transfer the 50% trypsin-EDTA + 50% PBS and α-MEM + 10% CS + 1% PS media 
solution from the plate to a 50 mL Falcon tube. 
13. Centrifuge the 50mL Falcon tube at 1000 rpm for 3 min at room temperature (22°C 
to 26°C).  Note: remember to balance the centrifuge with a water blank. 
14. Once the centrifuge is complete move the Falcon tube back into the hood.  Use a 
glass Pasture pipette and the vacuum pump to remove the supernatant from cell 
pellet that remains at the bottom of the tube. 
15. Add at least 10mL of α-MEM + 10% CS + 1% PS media to the cell pellet in the 
Falcon tube (Note: amount of media to use to re-suspend the pellet varies according 
to the number of plates available and type of experiment). Add the media slowly, and 
then pipette up and down until the pellet is broken up. 
16. Once cells are re-constituted in the α-MEM + 10% CS + 1% PS media add more 
media as needed for the number of new plates that the cells are being expanded to. 
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17. Add about 7 to 8 mL of α-MEM + 10% CS + 1% PS media to new plates, and then 
add your pre-determined amount of the α-MEM + 10% CS + 1% PS  containing the 
cells to each plate. Note: add the cells in small drops all around the plate so that the 
cells do not clump.  
18. Swirl the plates to ensure that the cells are evenly distributed. 
19. Label each plate with cell type and origin, passage number, initials, date, and plate 
number. 
20. Check plates under the microscope to ensure cells are evenly distributed in an 
appropriate confluency. 
21. Incubate the plates, clean up, and wipe down the hood with 70% ethanol. 
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Section II. siRNA transfection with Lipofectamine 2000 
 
1. The MC3T3-E1 cells (2,000 cells/well in a 96-well plate, 14,000 cells/well in a 24-well 
plate, and 70,000 cells/well in a 6-well plate) are plated in α-MEM +10% CS (100 µL 
of media/well for 96-well plate, 500 µL of media/well for 24-well plate and 2 mL of 
media/well for 6-well plate).   
2. Dilute the siRNA (10 pmols/well for 96-well plate, 40 pmols/well for 24-well plate, and 
200 pmols/well for 6-well plate) in Opti-MEM I Reduced Serum Media (25 µL/well for 
96-well plate, 50 µL/well for 24-well plate, and 250 µL/well for 6-well plate) and mixed 
gently. 
3. Mix the lipofectamine 2000 gently before use. 
4. Dilute the Lipofectamine 2000 (0.25 µL/well for 96-well plate, 1 µL/well for 24-well 
plate, and 5 µL/well for 6-well plate) in Opti-MEM I Reduced Serum Media (25 µL/well 
for 96-well plate, 50 µL/well for 24-well plate, and 250 µL/well for 6-well plate) and 
incubated for 5 min at room temperature. 
5. Combine the diluted siRNA and diluted Lipofectamine 2000 (to form the siRNA-
Liporectamine 2000 complex) as soon as possible and incubate for 25 min at room 
temperature. 
6. Add siRNA-Lipofectamine 2000 complex to each well (50 µL/well for 96-well plate, 
100 µL/well for 24-well plate, and 500 µL/well for 6-well plate). 
7. Incubate the plates for 24 hours at 37⁰C. 
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Section III. RNA extraction—Qiagen Kit 
 
1.  The transfected cells are grown in 6-well plates (70,000 cells/well). 
2. Tilt the plate of cells.  Using a glass Pasteur pipette and the vacuum pump, remove 
the media from the plate without touching the bottom of plate with the pipette tip.  
3. Tilt the plate and use a transfer pipette to gently add PBS to the plate, from the side 
wall. Then swirl the PBS over the plate to rinse the cells.  
4. Tilt the plate and using a glass Pasteur pipette and the vacuum pump remove the 
PBS from the plate. 
5. Add 1 mL TRI Reagent (trizol) to each well and scrape with pipet tip. 
6. Transfer it to a 1.5 mL microcentrifuge tube, vortex, and homogenize. 
7. Incubate for 5 min at room temperature. 
8. Add 200 µL chloroform to each tube and mix by inverting 5 to 7 times. 
9. Incubate for 2 to 3 min at room temperature. 
10. Centrifuge at 12,000 x g for 15 min. 
11. Transfer the aqueous phase (transparent, clear top layer) into a new micro centrifuge 
tube (approximately 500 µL). 
12. Add one volume (500 µL) of 70% EtOH to each tube and vortex the tubes. 
13. Transfer 700 µL of the sample into the RNA easy spin column. 
14. Centrifuge at 8000 x g for 30 seconds and discard the flow through. 
15. Add 700 µL Buffer RWI and centrifuge at 8000 x g for 30 seconds. 
16. Discard the flow through and the collection tube, and place the filter into a new 
collection tube. 
17. Add 500 µL of Buffer RPE and centrifuge at 8000 x g for 30 seconds. 
18. Discard the flow through and add 500 µL of RPE buffer. 
19. Centrifuge at 8000 x g for 2 min and discard the flow through. 
20. Centrifuge at 8000 x g for 1 minute. 
21. Discard the flow through and the collection tube, and put the filter into  a new capped 
collection tube. 
22. Add 50 µL of Rnase free water and centrifuge at 8000 x g for 1 minute.  
23. Take 35 to 40 µL from the collection tube and put back on the filter.  Centrifuge at 
8000 x g for 1 minute. 
24. Collect the eluted RNA and spec it in the Nanodrop spectrophotometer. 
25. Aliquot and store in the -800C freezer 
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Section IV. Normalizing the concentration of RNA to 300 ng/10µL 
 
Sample  
1. We need 300 ng/10 µL or 30 ng/µL of RNA to be used for reverse transcription. 
The final volume shoµLd be 26 µL (20 µL to be divided into two sets of reverse 
transcription and 6 µL for spectrophotometer analysis). 
C1V1= C2V2 
C2= 30 ng/µL 
V2=26 µL 
C1=concentration of RNA obtained after DNA-free treatment 
V1=? 
This calculation shoµLd give V1, the amount of stock solution of RNA to be taken.  The 
volume is corrected to 26 µL using nuclease free water. 
2. The RNA concentration shoµLd come to 30 ng/µL, variations are adjusted to 30 ng/µL 
by adding Nuclease Free water (0.5-1.0 µL) or adding RNA (0.2 µL). 
 
3. Transfer 10µL of normalized RNA (300 ng/10 µL) into one tube of an 8 tube strip (x 2) 
for reverse transcription. 
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Section V. Reverse transcription  
 
1. Thaw the reagents on ice (Ambion Oligo (dT), Invitrogen Superscript kit II containing 
DTT, 5X buffer and reverse transcriptase) 
2. Add 1 µL of Oligo (dT) to each 10 µL of normalized RNA sample (300 ng/10 µL) in 8 
tube strips. This makes it a total of 11 µL.NOTE: Include a Positive control too. 
3. Identify, or set the program on the PCR machine to run: 
70˚C for 10 min 
 4˚C for 20 min 
 37˚C for 3 min 
 42˚C for 1hr 
 4 ˚C for 3 min 
 90˚C for 2.30 min 
10˚C forever 
4. Run the tubes in the PCR machine and start step1, 70˚C for 10min. 
5. During step1, make the master mix (amounts are per sample, mµLtiply by the number 
of samples plus two for pipetting errors). 
Master Mix 
5X Buffer-  5.5 µL 
dNTP-        1.0 µL 
DTT-          2.0 µL 
Superscript II   0.5 µL 
NOTE: Add SS II last. 
6. Hit pause on the PCR machine when the temperature is dropping to 4˚C. 
7. Take the samples with RNA and Oligo (dT) out of the machine and keep on ice. 
8. Add SSII to the master mix, and mix gently. 
9. Add 9 µL of master mix to each sample, making it a total of 20 µL (keep samples on 
ice while adding the master mix). 
10. Place the samples back into the machine, hit “proceed” and hit “proceed” again to 
move to step # 3. The step #2 is skipped. 
11.  When reverse transcription is complete add 80 µL of Nuclease free water to 
samples and store in -20˚C freezer. 
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Section VI. Polymerase Chain Reaction (PCR) 
 
1. Thaw reagents on ice (Promega Green Master mix, Tbx2 114 forward and reverse 
primer working aliquots, cDNA sample). 
2. Make Master mix (amounts are per sample, mµLtiply by the number of samples plus 
two for pipetting errors) 
Nuclease free water  5.5 µL 
Green master mix  12.5 µL 
Forward Primer 1.0 µL 
Reverse Primer  1.0 µL 
3. Into 8-tube strips transfer 20 µL of the master mix per tube. 
4. Into the same 8-tube strips add 5 µL of the cDNA per tube, making it a total of 25 
µL/tube. This shoµLd be done just before it is ready to go into the PCR machine. 
5. Place the tubes into PCR machine and run the program with the steps below: 
 94˚C for 3min 
94˚C for 30s 
60˚C for 1min 
72˚C for1min 
72˚C for 5 min 
10˚C forever 
6. Once the PCR is complete (about 2 and 1/2 hr), the sample is stored at 4˚C in the 8-
tube strips. 
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Section VII. Agarose gel electrophoresis 
 
Preparation of a 2% agarose gel (mini gel) 
1. Weigh out 1 g of agarose.  
2. Add it to a conical flask containing 50 mL of Tris-acetate-EDTA (TAE) buffer. 
3. To dissolve, heat the mixture in a microwave for about 1.5 min (solution starts boiling 
by this time). NOTE: take the flask out and swirl it every 30 seconds to avoid spillage 
and to aid proper dissolution. 
4. Allow the flask it to cool to about 50˚C to 60˚C (i.e. cool to touch). 
5. Add 3 µL of ethidium bromide stock solution (10 mg/mL) to the liquid gel. Gently swirl 
to mix. NOTE: WEAR GLOVES! Ethidium bromide is TOXIC MUTAGEN. Proper 
care is to be taken in disposal.  
6. Pour the liquid gel into the gel forming cassette. 
7. Place the combs at one end to form the wells, allow it to solidify (about 20 min). 
Loading the wells 
1. Load ladder to the first well: 1 µL of loading dye + 5 µL of DNA ladder (100bp ladder, 
Promega). The mixing can be done over a small piece of parafilm. 
2. 10 µL of sample (PCR products) are loaded into the rest of the wells. There is no 
need to add the loading dye to it, since the PCR product by itself contains the dye 
(green master mix). 
3. Fill the mingle apparatus with TAE Buffer. 
4. Close the lid, making sure that the electric field is generated as desired (Run to Red). 
5. Connect the electrodes to the battery and turn it on. Look for bubbles rising up on 
either side of the electrodes. 
6. Run it at 115 volts for about 45 min (i.e. until the dye front reaches almost bottom of 
the gel). 
7. Visualize the gel. 
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Section VIII. Real time RT-PCR 
 
1. Thaw the reagents (Syber green wrapped in foil, forward and reverse primers of 
Tbx2, PPIA, and any other targets, and cDNA) on ice. 
2. Turn the lights off before you begin the experiment. 
3. Make Master Mix (depending on the number of target genes). If Tbx2 and PPIA, then 
prepare two Master mixes (Eg. If 6 samples of cDNA, then two master mixes of each 
Tbx2 and PPIA for 8 reactions, 2 extra reactions for pipetting error) 
4. Amount per reaction:      
  2X Syber Green  10 µL 
Forward Primer  1 µL 
Reverse primer  1 µL 
NFree water       3 µL 
5. Add 15 µL of master mix to each well that you will be using in a 96 PCR optical plate. 
6. Add 5 µL of cDNA (diluted 1:5, 20 µL of cDNA + 80 µL of nuclease free water) to the 
previously identified tubes. Make sure to pipette to the bottom of the tube. 
7. Seal the plate with a PCR adhesive film tightly to prevent evaporation. 
8. Centrifuge the plate at 1,000 rpm for 1 to 2 min. 
9. Run it in Q-PCR Machine. 
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Section IX. Western Blot  
 
SDS-PAGE  
1. Take the casting stand and place the rubber bases (gray color) on them. 
2. Place the 1.5 mm glass spacer plates with the green holder on to a casting stand. 
(large   plate facing the casting stand and small plate facing you). (Use black clips to 
secure both sides of the plates carefully). 
3. Prepare resolving gel (12%) and use a 10 mL pipette to pour the solution between the  
1.5 mm spacer plates up to the mark (make sure you leave a 1 TO 2 cm gap). Pour 
300 µL of isobutanol to remove bubbles and to level the gel by dragging the pipette 
tip across (the isobutanol is more dense so it will float on top of the resolving gel 
solution). 
4. Allow the gel to solidify for 1 hour. Carefully remove the glass plates with the resolving 
gel from the green holder. Wash the plates with deionized water without separating 
plates. Take syringe and remove the isobutanol and wash thoroughly with water. 
Return the plates to the casting stand. 
5. Now place the glass plates with gel in to the electrode stand (Large plate facing you 
and the small plate facing the stand). Now use the blotting paper (3 mm 
chromatography paper) to remove the remaining water off the top of the resolving gel. 
6. Prepare stacking gel (4%) solution and pour on top of the resolving gel. Fill with this 
solution up to the top. Carefully insert a 10 well comb (1.5mm) (smooth side facing 
the large plate) and allow it to solidify for 30 min. Make sure there are no air bubbles. 
(comb-BioRad should be facing you after you turn apparatus)   
7. Turn on the hot water bath to 650C. 
8. Meanwhile, calculate the amount of sample required for loading the gel.  The sample 
will be loaded at 20 µL per well and the ladder will be loaded at 5µL of sample per 
well.  Each sample contains 3.3 µL of 6X loading dye, 20 µg of protein sample. The 
total volume will be adjusted with water. 
8. Vortex the sample tubes with the dye for 15 seconds. Place the samples in the hot 
water bath for 10 min. 
9. Remove comb carefully from the gel. Add ladder (5 µL) and samples (20 µL each) 
using sequencing pipette tips.  
10. Pour the running buffer into the apparatus. Close the unit and connect it to the power 
supply. Electrophoreses the samples at 100 volts for 150 min at 300 amps. 
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Transfer 
1. Carefully, take the gel out of the electrode assembly. 
2. Cut the top of the (stacking) gel using a blade.  
3. For each gel, cut two 3 mm chromatography paper (filter paper) and 1 PVDF or 
nitrocellulose membrane (cut according to the size of the gel). Make a small cut for 
the membrane on the right hand top corner. 
4. Wet the filter paper and the PVDF membrane in Milli-Q water for 5 seconds followed 
by soaking in transfer buffer (Tris/Glycine/Methanol) for 15 to 20 min.  
5. Wet the scotch pads (white pad that comes with the apparatus) in water and then in 
transfer buffer for 5 min. 
6. Make a sandwich:  
 -Open transfer cartridge (plastic case with white and black sides) 
 -Place the scotch pad, then filter paper, then gel on the black side of the catridge 
 - Carefully place membrane on the gel such that the right hand cut matches with 
              right side of the gel and roll out air bubbles with a glass pipette. 
-Place the other filter paper and scotch pad on top. 
- Roll air bubbles again with glass pipette. 
- Close and seal cartridge. 
NOTE: The gel and the membrane were stacked into a sandwich with scotch 
pads, presoaked filter paper membrane in such a way that the transfer of proteins 
occurs from the negative to the positive electrode.  
7. Place cartridge in transfer apparatus or Mini Transblot Electrophoretic Cell (Bio-
Rad Laboratories) (make sure that the black side of cartridge faces black side of 
the apparatus). 
8. Fill the apparatus with transfer buffer until the gel or membrane is covered.  
9. Add stir bar to the transfer apparatus and place the apparatus in a cold room on 
a stir plate. Turn on the stir plate and connect the apparatus to power.  
10. Transfer overnight at 25 volts in 40C or at 100 volts for 2 ½ hrs at room 
temperature. The membrane thus obtained was either used immediately or 
stored at 40C. 
 
Western Immunoblotting 
 
1. After transfer, take out the membrane from the cassette. 
2. Place the membrane with proteins in a container (usually lid of a pipette box) and 
blocking buffer (~ 10 mL) such that the membrane is fullly immersed in the buffer. 
Incubate the membrane in blocking buffer for 1 hour at 40C on a rocking platform. 
3. Wash the membranes three times for 5 min each wash with TBS/T. 
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4. After washing, add primary antibody (Tbx2 1: 500, abcam) to the blocking buffer (~10 
mL) with respective dilutions in a container. Incubate membrane in the primary 
antibody dilution overnight. 
5. Wash membrane three times for 5 min each wash with TBS/T.  
6. After washing, add secondary antibody (Anti Tbx2 1: 2000, abcam) to the blocking 
buffer (~10 mL) with respective dilutions in a container and incubate for 1 hour. 
7. Again wash the membrane three times for 5 min each wash in TBS/T prior to 
developing.  
 
Stripping  the membrane:  
Stripping the membrane enables the removal of the antibodies from the 
membrane without losing proteins and reprobing the same membrane with a different 
antibody. Each membrane can be stripped and reused 3 to 4 times. For example: 
stripping allows checking of the expression of the protein of interest as well as housing 
keeping gene on the same membrane. 
1. Wash the membrane for 5 times for 5 min each wash in TBS/T. 
2. Incubate the membrane in a plastic container with 10 mL of stripping buffer at 500C  
to 550C. 
3. Wash again in TBS/T twice with each wash lasting 5 min. 
4. Block the membrane with 5% non fat milk. 
5. Follow the same protocol for the regular western blotting from this step onwards. 
 
Buffers used for western blot 
10X TRIS/GLYCINE STOCK SOLUTION 
For 1000 mL of 10X Tris/Glycine: 
30 g Tris base 
144 g Glycine 
1000 mL Milli-Q H2O 
Need not autoclave/sterilize 
RUNNING BUFFER 
For 1000 mL 1X solution: 
100 mL 10X Tris/Glycine stock solution 
900 mL Milli-Q H2O 
Add 1g SDS  
Need not autoclave/sterilize 
TRANSFER BUFFER 
For 1000 mL 1X solution: 
80 mL of 10X Tris/Glycine stock solution 
720 mL of Milli-Q H20 
200 mL MeOH 
Need not autoclave/sterilize 
TRIS BUFFERED SALINE (TBS) 
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For 1000 mL 10X stock solution: 
24 g Tris base 
80 g NaCl 
1000 mL Milli-Q H2O 
Need not autoclave/sterilize 
TBS/T 
For 1000 mL 1X solution: 
100 mL 10X TBS 
1 mL Tween-20 
900 mL Milli-Q H20 
Need not autoclave/sterilize 
100mM Ammonium Per Sulfate (APS)  
54.9 mg APS 
549 µL of Milli-Q H20 
Dissolve and aliquot 100 µL into each MCF tube 
Store at -200C 
Do not use more than once after thawing.   
1.5 M TrisHCl pH 8.8 
For 500 mL 1.5M solution: 
Tris base 90.76 gm 
Add 450 mL Milli-Q water 
Adjust to pH 8.8 with HCl. 
Adjust volume to 500 mL with Milli-Q water 
Store at 4°C 
1 M TrisHCl pH 6.8 
For 500 mL 1 M solution: 
Tris base 60.57 gm 
Add 450 mL Milli-Q water 
Adjust to pH 6.8 with HCl. 
Adjust volume to 500 mL with Milli-Q water 
Store at 4°C 
0.5 M TrisHCl pH 6.8 
For 500 mL 0.5M solution: 
Tris base 30.5 gm 
Add 450 mL Milli-Q water  
Adjust to pH 6.8 with HCl. 
Adjust volume to 500 mL with Milli-Q water  
Store at 4°C. 
Sodium Dodecyl Sulfate (SDS )  
For 100 mL 10% SDS stock solution: 
10 g electrophoresis grade SDS  
Add the powder carefully to 90 mL Milli-Q H2O 
 Place the container in a 65°C water bath (with frequent stirring) or a hot plate stirrer to 
dissolve the SDS.  
When SDS has dissolved, bring volume to 100 mL Milli-Q H2O.  
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Do not autoclave/sterilize. Store at room temperature (At room temperature SDS 
solidifies. Before use, reheat to dissolve). 
30% Acrylamide/ 0.8 % Bis-acrylamideFor 100 mL solution: 
Acrylamide 30 gm 
N'N'-bis-methylene-acrylamide 0.8 gm 
Adjust volume to 100 mL with Milli-Q water 
Sterilize the solution by filtration through a filter (0.45 micron pore size) 
Store in amber bottle at 4°C in the dark (30 days max) 
Blocking Buffer: 
To a 50 mL tube add  
5 mL 10XTBS 
45 mL Milli-Q water 
2.5 gm skim milk  
50 µL Tween  
Stripping Solution: 
For 100 mL of stripping solution: 
12.5 mL of 0.5M Tris-HCl 
20 mL of 10% SDS 
700 µL of b-mercaptoethanol 
Adjust the volume to 100 mL with dH2O 
 
Reagents Resolving Gel Stacking Gel 
 20 mL 10 mL 20 mL 10 mL 
1.5 M TrisHCl pH 8.8 5 mL 2.5 mL -------- --------- 
0.5 M TrisHCl pH 6.8 -------- -------- 5 mL 2.5 mL 
Distilled water 6.7 mL 3.35 mL 10 mL 5 mL 
10% SDS 200 µL 
 
100 µL 
 
100 µL  50 µL  
30% Acrylamide/Bis-
acrylamide 
8 mL 4 mL 2.4 mL 1.7 mL 
100mM APS 
(Ammonium 
Persulfate) 
(freshly prepared) 
100 µL  50 µL  100 µL  50 µL  
TEMED 10 µL  5 µL  10 µL  5 µL  
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Coomassie Brilliant Blue Staining on PVDF/Nitrocellulose Membrane: 
For 1L staining solution add the following: 
0.5% Coomassie brilliant blue ( 0.5 g )  
40% methanol (400 mL)  
10% acetic acid (100 mL) 
  Q/S with milli-Q H2O to 1000 mL 
Destaining Solution 
For 1L destaining solution add the following 
30% methanol (300 mL) 
10% acetic acid (100 mL) 
Q/S with milli-Q H2O to 1000 mL 
Gel Staining/Destaining Protocol 
Stain gel/membrane in CBB solution for 30 min on shaking platform  
Destain until background is transparent and bands are visible  
Wash gel 3 to 5 times with H2O 
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Section XI. alamarBlue assay  
Day 0 (Plating cells in 10% calf serum) 
1. The cells are passed once (as per the Cell passage protocol) before plating. 
2. Cells are collected from the plates, centrifuged at 1,000 rpm for 2 to 3 min, 
resuspended in 10 mL of media and finally counted using a haemocytometer. 
3. A 96 well plate is plated at a concentration of 2,000 cells/well in 50 µL/well of media. 
Day 1 (Cells in serum free environment) 
1. Stock Media (α-Minimal Essential Medium, MEM + 0.1% Bovine serum albumin, BSA 
+ 1% Pencillinstreptomycin ) is thawed in water bath at 37⁰C. 
2. Dump off the media in 96-well plate on to a paper towel placed in fume hood. 
3. Load 50 µL of media to all the wells, mix gently, and dump it off. 
4. Load 50 µL of media to all the wells and mixe. 
5. Place the plate in a 5% CO2 incubator at 37⁰C. 
Day 2 (Treatment of cells) 
1. Layout a design for the control and different treatment wells (stock media with 0.1% 
BSA-control, 0.1% CS, 0.5% CS, 1.0% CS, 5.0% CS, 10% CS etc. – treatment 
wells). 
2. Prepare treatment groups with different concentrations of calf serum and stock 
media in 15 mL tubes. (Be sure to make double the volume required for each 
treatment group). 
3. Dump off the media in 96 well plate on to a paper towel placed in fume hood. 
4. Load 50 µL of control and treatment media to the designated wells using a 
multipette. 
5. Mix gently and kept in CO2 incubator. 
Day 4 (alamarBlue assay) 
1. Set Synergy 2 to read plate to allow for warm up. 
2. Dump off the media (control and treatment) in 96 well plates. 
3. Rinse all the wells with 100 µL of PBS. 
4. Dump off the PBS, and re-wash with another 100 µL of PBS. 
5. Add alamarBlue indicator to plain α-MEM medium in 1:10 dilution ( 9 mL of α-MEM + 
1mL of alamarBlue  for  96 wells) NOTE : Take care not to expose alamarBlue to 
sunlight.  Add alamarBlue indicator just before wells are loaded, keeping it in 
fumehood for a long time greatly reduces activity. 
6. Dump off the PBS from the 96 well plates. 
7. Load 100 µL of solution (α- MEM + alamarBlue) to all wells and mix gently. 
8. Wrap the plate with aluminum foil and placed in CO2 incubator. 
9. After 4 hours, fluorescence is detected by Biotek plate reader 540/35 x 600/40 nm, 
Sensitivity 54. 
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Section XII. BrdU assay 
 
Day 0 (Plating cells in 10% calf serum) 
1. The cells are passed once (as per the Cell passage protocol) before plating 
2. Cells are collected from the plates, centrifuged at 1,000 rpm for 2 to 3 min, 
resuspended in 10 mL of media and finally counted using a haemocytometer. 
3. A 96 well plate is plated at a concentration of 2,000 cells/well, 50 µL media/well. 
Day 1 (Cells in serum free environment) 
1. Stock Media (α-Minimal Essential Medium, MEM + 0.1% Bovine serum albumin, 
BSA + 1% Pencillin-streptomycin ) is thawed in water bath at 37⁰C. 
2. Dump off the media from the 96-well plate on to a paper towel placed in fume hood. 
3. Load 50 µL of media to all the wells, mix gently and dump it off. 
4. Load 50 µL of media to all the wells and mixed. 
5. Place the plate in 5% CO2 incubator at 37⁰C. 
Day 2 (Treatment of cells) 
1. Layout a design for the control and different treatment wells (stock media with 0.1% 
BSA-control, 0.1% CS, 0.5% CS, 1.0% CS, 5.0% CS, 10% CS etc. – treatment 
wells). 
2. Prepare treatment groups with different concentrations of calf serum and stock 
media in 15 mL tubes. (Be sure to make double the volume required for each 
treatment group). 
3. Dump off the media in 96well plate on to a paper towel placed in fume hood. 
4. Load 50 µL of control and treatment media to the designated wells using a 
multipette. 
5. Mix gently and return to the  CO2 incubator. 
Day 4 (alamarBlue assay) 
1. Add 10 µL/well BrdU labeling solutions to the plate and incubate for 2 hrs at 37⁰C. 
2. The labeling solution is removed. 
3. Add 200 µL/well FixDenat to the cells and incubate for 30 min at room temperature. 
4. Remove the FixDenat soution. 
5. Add 100 µL/well Anti-BrdU-POD working solution and incubate for 90 min at room 
temperature. 
6. Excess antibodies are removed by dumping off the solution and rinse the wells three 
times with 200 µL/well of washing solution. 
7. The washing solution is dumped off. 
8. The bottom of the plate is sealed with a black adhesive film. 
9. Add 100 µL/well of the substrate solution to each well. 
10. The plate is incubated for 5 min at room temperature. 
11. The luminescence is read at BioTek plate reader with auto sensitivity 
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Section XIII. Alkaline phosphatase (ALP) assay 
 
Day 1:  Plate cells 
1. Plate cells at 5,000 cells/well in 96 well plate in α-MEM + 10% CS + 1% PS at 100 
µL/well. 
2. Incubate for 24 hours at 37⁰C. 
Day 2:  Change to serum free media 
1. Rinse with 100 µL of  α-MEM + 0.1% BSA + 1% PS two times.  
2. Make a stock media with 10 mL of α-MEM + 0.1% BSA + 1% PS, 100 µL Vit C 
(AA2P), and 100 µL β-glycerophosphate.  
3. Add 100 µL/well of the above solution and incubate for 24 hours. 
Day 3:  Add Appropriate Growth Factors 
1. Make a stock media of 5 mL of α-MEM + 0.1% BSA + 1% PS, 50 µL Vit C (AA2P), 
and 50 µL β-gal (or make 10 mL as needed). 
2. Used the above media and to make your treatments. 
3. Remove old media from wells without rinsing. 
4. Add 100 µL/well for control and treatments and incubate for 72 hours. 
Day 6:  Permealize the cells and perform ALP assay 
1. The procedures for this day can be performed under non-sterile conditions.   
2. Dump off the media from the cells. 
3. Rinse two times with warm PBS using 100 µL/well. 
4. Add 100 µL of 0.1% triton to each well. 
5. Shake at medium speed at room temperature for 15 to 20 min. 
6. Wrap in a parafilm. 
7. Freeze at -80°C for at least 15 min (optional – after shaking the cells can be stored 
at -80°C until future use). 
8. Obtain two 96 well plates. 
9. Thaw the ALP substrate by placing the tube in the water bath and also thaw out the     
96-well plate at room temperature. 
10. Scrape the cells using the tips on a multipipettor and pipette mix the cell lysates. 
Make sure that no bubbles are contained in the pipette tip when the lysate is 
transferred to the new 96-well plate:  Set multipipettor to 40 µL, hold the button on 
the pipettor down then begin scrapping the wells; once well is sufficiently scrapped 
release the button and remove the lysate from the well.   
11. Transfer 40 µL of the cell lysate (for ALP) into one 96-well plate.  
12. For protein analysis add 80 µL Distilled H2O then add 20 µL of the cell lysate (for 
protein concentration) into one 96-well plate. 
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ALP activity 
1. Prepare two Blank wells with 40 µL of 0.1% Titron/well. 
2. Add 200 µL of the ALP Substrate to all of the wells (including blank). 
3. Immediately read (0 hour) absorbance at 405 nm, and then  incubate at 37°C and 
read after 5 hours of incubation. 
Protein estimation 
BLANK- in the next available column, make two blank wells.  First well: 20 µL of 
0.1%Triton and 80 µL of Distilled H2O.  Second well: 100 µL of Distilled H2O 
SAMPLE- 20 µL lysate and 80 µL Distilled H2O.  (H2O added first) 
DYE- 2 mL Bio-Rad Protein Assay Reagent and 8 mL H2O (1:5 dilution) 
 STANDARDS-  
Stock:  100 µg BSA/ 1 mL dH20 = for example:   30 mg BSA/300mL dH2O 
1. Of the 300mL stock take 150 µL and add 150 µL dH2O 
{final concentration is 50 µg/mL} 
2. Of the resulting solution take 150 µL and add 150 µL dH2O  
{final concentration is 25 µg/mL} 
3. Of the resulting solution take 150 µL and add 150 µL dH2O  
{final concentration is 12.5 µg/mL} 
4. Of the resulting solution take 150 µL and add 150 µL dH2O  
{final concentration is 6.25 µg/mL} 
5. Of the resulting solution take 150 µL and add 150 µL dH2O  
{final concentration is 3.125 µg/mL} 
 
1.  Into the next available column add 100 µL of each standard/well (7 wells total; 
include  100 µg/mL(from stock) and 0 µg/mL(distilled H2O)) 
2. Add 200 µL of the dye to all wells on the plate. 
3. Incubate the plate for 5 min and read the plate absorbance at 595 nm. 
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